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The cloning of a number of mammalian Gonadotropin-Releasing-Hormone receptors 
(GnRH receptors) revealed a high homology amongst this group of receptors (>85% 
sequence identity) and very similar pharmacology [1]. However, the effects of GnRH 
analogues on hormone release from primary cultures of pituitary cells indicated that 
non-mammalian GnRH receptors have distinctively different pharmacologies [2]. The 
recent cloning of non-mammalian GnRH receptors from catfish [3], goldfish [4, 5], frog 
[6, 7] and chicken [8] confirmed this fmding. Notable differences between the 
mammalian and some non-mammalian GnRH receptors were that certain agonists have 
different affinities and efficacies. Another difference was that certain antagonists of the 
mammaHan receptors behaved as partial or full agonists in the chicken GnRH receptor 
[2,8]. This is also true of the Xenopus laevis GnRH receptor (unpublished). It has been 
demonstrated that GnRH binds to the extracellular loops and the superficial regions of 
the transmembrane domains (review in ref. [1]). It was therefore considered likely that 
extracellular loop domains (ELs) of the different receptors would playa role in the 
recognition of certain ligands and consequently in determining agonist and antagonist 
activity of ligands. 
In this study the possible role of extracellular domains in conferring agonist activity to 
one of these ligands (Antagonist 135-18) was investigated. Silent mutations close to the 
extracellular end of the transmembrane domains were introduced into the human GnRH 
receptor to create restriction endonuclease cutting sites that could be used to exchange 
ELs. ELs of the X laevis GnRH receptor were amplified by PCR using primers 
containing the engineered restriction endonuclease recognition sequences. The PCR 
products were then used to replace ELs of the human GnRH receptor. The resultant 
chimeric receptors were transiently expressed in COS-l cells and their pharmacologies 
were determined. Antagonist 135-18 was found to have agonist activity in the chimeric 
receptor where EL-2 had been replaced. Human receptors possessing either the X laevis 
EL-l or EL-3 still recognised Antagonist 135-18 as an antagonist. These finding 
implicate the X laevis EL-2 as the arbiter of agonistic activity of Antagonist 135-18 at 
the chimeric receptor. Chimeric receptors where only parts of EL-2 were replaced 
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indicated that both the N- and C-tenninal sections ofEL-2 conferred partial but not full 
agonist activity to Antagonist 135-18. 
In a previous study it has been shown that a positively charged D-Lys or D-Lys(iPr) is 
needed in position 6 of the antagonist to be recognised as an agonist in the chicken 
GnRH receptor [8]. It was therefore possible that there would be a counter-ion in EL-2. 
From comparisons of non-mammalian GnRH receptor sequences a conserved Glu was 
identified at the C-terminal end of EL-2, which was not present in the mammalian 
receptors. When Glu in the equivalent position of the human GnRH receptor was 
mutated, however, Antagonist 135-18 was still recognised as an antagonist. Mutations 
of each of the other residues in the C-terminal section of EL-2 gave similar results. A 
series of human GnRH receptors containing multiple mutations showed that the 
minimal and essential structural determinant in the C-terminal domain of EL-2 for 
conferring agonist activity to Antagonist 135-18 is a His20S combined with Alal97• It is 
proposed that D-Lys(iPr) in position 6 of the ligand forms a charge supported hydrogen 
bond with His20s which cannot occur between the human wild-type receptor and 
Antagonist 135-18. A small Ala side chain might be needed in position 197 to overcome 
sterlc problems compromising the interaction when a larger side chain is present. This 
additional interaction presumably allows the receptor to be stabilised in the active 
conformation. 
Results presented here, combined with computer modelling and results from future 
experiments which are based on this work can ultimately be used to refme the model of 
receptor activation. Understanding mechanisms involved in the recognition of ligands as 
agonists or antagonists are of importance for the design of novel pharmaceutical agents, 
which could be used in the treatment of diseases. 
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CHAPTER 1: INTRODUCTION 
Background 
Gonadotropin-Releasing-Hormone (GnRH1) is a decapeptide (pGlu-His-Trp-Ser-Tyr-
Gly-Leu-Arg-Pro-Gly-NH1) released from the hypothalamus to target its cognate 
receptor in the anterior pituitary. By activating its receptor it regulates the production of 
gonadotropins, follicle stimulating hormone (FSH) and luteinising hormone (LH), 
therefore having a pivotal role in the control of the reproductive system [1, 10, 11]. 
Because of this central role in reproduction, GnRH analogues have been used in the 
treatment of a wide spectrum of hormone dependent diseases including poly-cystic 
ovarian syndrome, hirsutism, porphyria, uterine fibrosis, precocious puberty, infertility, 
endometriosis, endometrial-, breast-, ovarian- and prostate cancer [12]. These analogues 
may also show promise in the development of a new generation of contraceptives. 
However, there are a number of disadvantages with using these peptide GnRH 
analogues. Since these analogues are peptides they have to be administered by injection. 
Depots are a means to overcome multiple injections and to ensure compliance but 
patients are not able to stop the treatment when desired [12]. Most of the analogues 
currently in use are agonists that operate through desensitisation but they initially 
stimulate the reproductive system for several weeks before the onset of desensitisation. 
GnRH antagonists are not widely used at present as much higher doses than agonists are 
required (several mg per day, as opposed to f,Lg per day for agonists) [12]. An alternative 
to peptide analogues, which would solve these problems, would be to use non-peptide 
orally active small molecules. The delineation of the ligand binding pocket and 
mechanisms involved in the stabilisation of the active and inactive conformation of the 
GnRH receptor may contribute in this quest. 
1 for abbreviations, see page 10 
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G protein-coupled receptors 
GnRH receptors belong to the superfamily of 0 protein-coupled receptors (GPCRs) [13, 
14]. GPCRs form a large functionally diverse family of receptors. GPCRs can be 
grouped into three major families: the rhodopsin! p-adrenergic- (family A), glucagon 
receptor related- (family B) and metabotropic glutamate- (mGlu-) (family C) families. 
In addition there are another two minor subfamilies of yeast pheromone receptors 
(families D and E) and a subfamily comprising of four cAMP receptors from 
Dictyoslelium discoideum (family F) [15]. Knowledge of mechanisms underlying ligand 
binding and receptor activation in the family of GPCRs is essential to understand 
molecular mechanisms underlying GnRH receptor functioning. This introduction 
mainly focuses on ligand binding and receptor activation in the general context of the 
largest of the six GPCR families: the rhodopsinlp-adrenergic like GPCRs or family A, 
of which the GnRH receptor is a member. The GnRH receptor is also reviewed and 
mechanisms of ligand binding and receptor activation will be compared to what is 
known from other GPCRs. 
Structural features of GPCRs 
General structural features of GPCRs and mode. of the transmembrane 
domains 
The GPCR family of receptors is characterised by comprising seven hydrophobic 
helices that are proposed to form a helix bundle crossing the cellular lipid bilayer. The 
N-terminal domain is extracellular, the C-terminal domain intracellular, and the seven 
helices, or transmembrane domains (TMDs), are connected by alternating intracellular 
loop domains (ILs) and extracellular loop domains (ELs) (Figure 1). The loops 
connecting TMDs are as short as 5-12 amino acids in certain receptors. It is therefore 
understood that consecutive helices are neighbouring in the three-dimensional 
configuration arranged in a counter-clockwise fashion as seen from the extracellular 
side of the cell (reviewed in ref. [1, 16, 17]). A hydrophilic pocket is found at the core 
of the transmembrane helix bundle that is maintained by a number of structural features 
of the individual helices. The different helices may vary in length: TMD-III, -V and -VI 
have been proposed to be longer than the other TMDs and therefore extend beyond the 
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lipid bilayer into tllc cytosol (15. 18). It has also been sUi;il:sled thai some lNIOs, 
notably TMDs I-Ill. are no\ perpendicular but tilled within the membrnne [I S. 18·20 1 
(Figure 2). ",hile Pro residucs within ThIDs are able to L: ink helices up to 30" r I S. 18. 
201. II has bc:t:n furlhcnnon: !\hown by [ow resolution density mops that the helix bundle 
is tightly packalllllhe intracellular side oflhe memhr-.me. Near the extracellular side 
Inc belix bundle is opened up mon: fomling II; hydrophilic cavity moinly fonned b)' 
TMOs Il l-VI [15.201 .
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t1.&r. I, Primary lit""'"'' of Ih~ !\-adr.ne'i1c """'pi"", which il I rcpre..enlilin member of 1M 
rhodopsin family ofGPCR>. TMIh ore oonnt<1od by aI~, .... '''I ............ u~ll'" Joopo. 
l'h. N·lerminllS I, on the '''\010011"1..-. and 1 .... C~rnIl""" is Oft 'he InInceliulu 10, of.-
mtmbtan. Reli.!,,", in,""~.d in lig_ I",>dina are ~ .. 'n in Mid • ..". _ CCIfIHI', .. d 
.ukl"". of GPCRs " 'jlllin each TM[) .. sbo .. n in mi. 81 ... rrsid ......... 100 vuy t'CIn!oft"cd 
.nd "'iI! be d,scus .. d in tho ~Re~pI" OCI"'lIIim~ K't1ion. Cllftn resld_ lire ,Iyrosyllllim 
Si1U. Tho p"lmilO~I.1iof1 ,i~ on tho C·lenninll 1.011 I, .1.., indiulcd. TM _/lor ... in !he 
.... mbnnt i. prcposN 10 form • fowth i..,.,.IM .......... 
As it has been impossible up to a now to obtain a thm:-dimcnsional crystal StruCture: of 
GI'CRs. a number ofthc:oretkal approao.;n."s suggesting a thr«·dimcnsionnl model hnlle 
been brought fOf\\.-ard 19, 21.241. These models 1l!"e mainly based on II proja:tion density 
map of rhodOp5in ... ith a resolution o f 7.S·9.oA ([19. 20, 2SJ. Figure 2). BaldWin 
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assullled lhal hydrophobic side chains should be facing the lipids of the membrane 
while polar side chains ofarnino acids in the TMDs should ei ther be facing inwards 
and/or towards Olher TMDs forming a hydrophilic pocket at the centre o f the helix 
TMO.v 
r,~U'" 2, Projection deouity map of 
bo .. i"e rhodopsin .. 9A. Th's fi&ure 
was taken from Schonter and 
Hargrav. 1251 and illustratu the 
."",nltoment of the helice. in the 
transmembrane bundle as """" from 
,It.< ;n,;"" "ftll< ""II. 
bundle. MOreoV.;oT. residues Iha1 are not conserved 
between closely related GPCRs should be fairly 
unimponant and therefore facing Ihe lipid bila)·,:r 
[2]]. Comparing 204 different OpeRs. Baldwin 
identified clear hydrophobic and hydropllilic faces 
of each helix [23). Changes amongst closely 
related orcRs ()(!cur mainly on the hydrophobic 
faces. Looking aI the s ize of the hydrophobic and 
hydrophilic faces it was fo und Ihal TMD-J. 
TMO-I V and TMO-V should be most exposed 10 
the lipid "hile TMO·[[] should be least ex(lOst'<l. 
Thcsl.' findi ngs toge ther wilh the projection 
d~nsity map of rhodopsin and information obtained from mutagenesis slOdies on ligand 
binding aoothe struclural integrity ofGPCRs provides us with a rdatively crude model 
of the arrangement of 1m: transmembrane he lix bundle [23/. The other models were 
drown up \\;th more emphasis on computer based modelling [21. 22, 24/. Infonnation 
from expcrim~nls thai idcntilied ligand-receptor- and intru·moleeular interaclions wer~ 
analyscd b)' compuler 10 draw up three-dimensional models. These models wi l] be 
progressively relined as fleW experim~ntaJ data becomes access ible. On the comr3/)' it 
has been much more difficult 10 model the ~xtra- a l}(! inlr'Jcellular domains of GPCRs. 
One of Ihe major problems is the lack of I;onservation of theSt; domains amongst all 
GPCRs. While TMIJs are 20-25% homologous amongsl GPCRs and 80-85% llI110ngSI 
GrCRs of different spe<:ics. hardly any homology con be idenli fied for intra- or 
extracellular domains even amongst closely related receptors [ 17] . The lack of 
conservation. both of lhe amino ocid sequence and the length of the loops, is somewhat 
surpri sing for the intr<lce llular loop domains as th<!y couple to the same heteromeric 
G proteins although a consensus site for the coupling of G, has been identified (26). 
Since there is lillie homology in Ihe primary structure, it has been difficult 10 model 
th~s<: loops with any re liabi lity. II has also been suggest~d litallrre cytoskdeton [27J or 
RGS proteins (regulotors of G protein signals) may playa major role in G protein 
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coupling. Interactions of G proteins with the receptor are beyond the scope of this thesis 
and are therefore only covered where necessary. 
Some of the most conserved amino acids amongst GPCRs are two Cys residues at the 
end of EL-l and in EL-2 respectively [17]. These two residues are proposed to form a 
disulphide bond important for the structural integrity of GPCRs. Mutant receptors 
lacking this disulphide bridge are generally poorly expressed [28-30], but the function 
other than structural is not properly defmed. These fmdings are in contrast to the 
AT I-angiotensin II receptors where mutations of extracellular cysteines do not affect 
expression and affect agonist but not antagonist binding [31]. It is possible that this 
brldge between EL-l and EL-2 might be involved in receptor activation as it connects 
TMD-IIIIII with TMD-N N and might act like a hinge that is important for the proper 
movements of all TMDs during receptor activation. Cys residues have also been 
identified in TMDs but no specific pairs that might stabilise the conformation of the 
helix bundle has yet been identified. [18]. 
Other conserved residues amongst GPCRs are prolines in TMD-IV, -V, -VI and -VII 
[17]. Because of sterlc clashes and a lack of hydrogen bonding capabilities due to its 
configuration, prolines are expected to break or at least kink a-helices. Since prolines 
are conserved within helices throughout all GPCRs they are believed to be important in 
forming the hydrophilic ligand binding pocket and/or being involved in receptor 
activation by maintaining the correct overall structure and by maintaining the proper 
positioning of helices [32,33]. It is also feasible that by bending the helices prolines are 
important in amplifying conformational changes associated with receptor activation. Pro 
in TMD-VII on the other hand is proposed to act as a flexible hinge that is needed for 
receptor activation ([32], discussed below). 
Amino acids conserved throughout GPCRs, other than proline, are Asn in TMD-I, Asp 
in TMD-II, Arg in TMD-III, Trp in TMD-IV and Asn in TMD-VII [17]. Most of these 
residues are also proposed to form part of the polar pocket [34] and seem to be 
important in receptor activation [15, 34-36] or in maintaining the structural integrity of 
GPCRs [34, 37] and will be discussed in greater detail under "Activation of GPCRs". In 
this chapter the focus will be on the activation of the receptors themselves. Residues and 
molecular processes involved in making contact and converting the inactive G protein 
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to its active confonnation are very complex and beyond the scope of this thesis. They 
are the subject of excellent review articles [16, 38-40] and will therefore only be dealt 
with where necessary. 
Post-translational modifications of GPCRs 
Consensus N-linked glycosylation sites (Asn-X-Serrrhr) can be found in the 
N-terminus of most GPCRs [17]. It has been shown recently that some GPCRs also 
contain O-linked oligosaccharides. However, no consensus sequence has yet been 
identified for this O-glycosylation [41, 42]. It has been suggested that there are 
chaperone proteins, like calnexin and calreticulin, in the endoplasmatic reticulum which 
anchor proteins, by recognising their carbohydrate moieties, until they are folded 
correctly [43, 44]. The function of glycosylation varies amongst GPCRs. It has been 
shown that glycosylation affects expression but not ligand binding in the GnRH- [45], 
fJ-adrenergic- [46], Via-vasopressin- [47] and FSH [48] receptors. For other GPCRs, 
like rhodopsin [49], the thrombin- [50], EP3a-prostaglandin E2- [51], J1-opioid [52], 
TSH- [53] and Gastrin-Releasing-Peptide (GRP) [54] receptors, however, glycosylation 
has been implied for being involved in ligand binding, selectivity and/or G protein 
coupling. Furthermore glycosylation has no known function in the NKI-Neurokinin-
[55], M2-muscarinic-acetylcholine- [56], histamine H2- [57], oxytocin- [58], ATI- [31] 
and AT2-Angiotensin II [59] receptors. Although glycosylation of the N-terminal 
domain is found in almost every GPCR, its function varies considerably between 
different receptors. Despite being a conserved feature of GPCRs, its function has 
therefore not been conserved throughout evolution. 
A number of phosphorylation consensus sequences can be found in the C-terminal tail 
of most GPCRs and to a lessor extent in IL-3. Upon receptor activation these sites are 
phosphorylated by members of the G protein-coupled receptor kinase (GRKs) family 
and second-messenger-activated protein kinases such as protein kinase A (PKA) and 
protein kinase C (PKC) [60]. Phosphorylation of the receptor diminishes its ability to 
activate G proteins and enables fJ-arrestin to bind to the receptor [61]. The receptor-
fJ-arrestin complexes are sequestered and internalised through clathrin coated pits. 
Internalised receptors may ultimately be degraded or dephosphorylated and recycled to 
the cell surface [62]. It has been suggested that p-arrestin is not only responsible for the 
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sequestration of GPCRs but also for triggering a second wave of signalling similar to 
that of receptor tyrosine kinases [63]. It is believed that JJ-arrestin recruits members of 
the Src family of tyrosine kinases, which are involved in the activation of mitogen-
activated protein (MAP) kinase [63]. These pathways, however, are not the scope of this 
thesis, and are therefore not dealt with in detail. 
Another post-translational modification is palmitoylation. There are a number of semi-
conserved Cys residues in the C-terminal tail [17]. These residues seem to be important 
in maintaining the tertiary structure of GPCRs, not by forming disulpbide bridges but by 
being palmitoylated. Palmitoylated cysteines are believed to anchor the C-terminal tail 
in the plasma membrane thereby producing extra intracellular loops (e. g. in the 
adrenoceptors [17] and rhodopsin [64]) (Figure 1). The additional loops seem to have 
major function in the mobility of GPCRs in the membrane and in coupling of GPCRs to 
their cognate G protein. This, however, is not a consistent model as, e. g. the 
mammalian GnRH receptors do not contain C-tenninal tails in the cytoplasm. 
Dimarlaation of GPeRa 
Dimerisation is essential for signalling of many classes of cell surface receptors. Early 
indications that GPCRs may also form dimers (from cross-linking studies [65, 66] and 
receptor affinity labelling [67, 68]) reaches back as far as 20 years. These fmdings, 
however, attracted much controversy as they challenged classical models of GPCR 
functioning, in which one ligand interacts with only one GPCR. 
More recently a more direct approach has been taken to show dimerisation. In one 
instance the domains from TMD-VI onwards of the <X2-adrenergic receptor were 
replaced by the equivalent domains of the M3-muscarinic-acetylcholine receptor. This 
receptor was unable to bind adrenergic ligands and signalling was abolished [69]. 
Similarly, when the domains from TMD-VI onwards of the M3-muscarinic-
acetylcholine receptor were replaced by the equivalent domains of the <X2-adrenergic 
receptor no binding or signalling could be detected for this receptor either. Co-
transfection of these two defunct chimeric receptors, however, restored binding for both 
adrenergic and muscarinic ligands as well as signalling [69]. In a similar experiment 
two point mutations of the ATI-angoitensin II receptor exhibited impaired binding. 
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Upon co-expression of these two mutant receptors binding was restored [70]. These 
experiments imply that intermolecular contacts between two defunct receptors may 
restore the binding sites. 
Further evidence for dimerisation of GPCRs was derived from co-immunoprecipitation 
experiments. Western blots often showed bands that might correspond to complexes of 
two or more equivalents. This, however, is no proof for dimers to occur, as receptors 
could bind to other proteins as well. For the dimers to be detected under conditions 
containing SDS also poses questions about whether these complexes can be found under 
physiological conditions. To show that the obtained high molecular weight bands were 
indeed from GPCR dimers, Hebert et al co-transfected fll·adrenergic receptors that 
contained either HA or Myc tags [71]. Upon immunoprecipitation of receptors 
containing the Myc tag, HA tagged receptors could also be detected in the high 
molecular weight bands [71]. HA tagged M2·muscarinic·acetylcholine receptors could 
not be detected in high molecular weight bands when co-transfected with Myc tagged 
a2-adrenergic receptors indicating that a2·adrenergic receptors are able to form 
homodimers but not heterodimers with M2-muscarinic-acetylcholine receptors [71]. 
The most recent demonstration of GPCR dimer formation comes from bioluminescence 
resonance energy transfer (BRET) experiments in living cells [72]. Upon agonist 
exposure of cells co-transfected with fll-adrenergic receptors which were fused to either 
green fluorescent protein (GFP) or Renilla luciferase (RLuc), fluorescence at 520 nm 
increased indicating that the agonist either promotes the formation of dimers or changed 
the conformation in existing dimers [72]. 
It has also been shown that the GABAB receptor requires two types (Rl and R2) for 
proper expression and functioning. GABABRI expressed by itself is retained 
intracellularly as an immature glycoprotein. Co-expression with GABABR2, which by 
itself is also inactive, leads to a functional receptor that is expressed on the cell surface 
[73-77]. GABAaR2 therefore acts as a chaperon for the maturation and/or cell surface 
expression of the GABAaRl receptor, but it is unclear whether the dimer is required for 
signalling. 
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The formation of heterodimers has also been proposed for K- and 8-opioid receptors. 
The resulting heterodimer showed characteristics different from any of the wild type 
receptors [78]. Heterodimerisation could therefore contribute to pharmacological 
diversity. Further strength has been added to this line of argument by the observation 
that the &-opioid receptor was unable to undergo agonist dependent intemalisation upon 
co-expression with a dimerisation defective mutant &-opioid receptor [79]. Additionally 
it has been shown that wild type receptors may lose their function when co-transfected 
with receptors that contain inactivating mutants [80-82]. 
In summary, it can be seen that GPCRs are likely to fonn dimers. Proposed roles for 
this dimer fonnation are in receptor maturation, -trafficking, -intemalisation and 
signalling. How dimerisation may affect these pathways, the 3D arrangement of dimer 
complexes and whether the process of dimerisation is dynamic, however, remains 
largely unknown, as there is little support to validate the above models. 
Nomenclature 
Since GPCRs are different in size a common numbering system is needed to be able to 
compare residues across different receptors. For the remainder of this thesis the 
numbering system proposed by Ballesteros and Weinstein [9] will be used. The most 
conserved residue of a TMD is assigned the number SO. For example the most 
conserved residue in TMD-III is therefore assigned the number 3.50 (see Figure 1 for 
the most conserved residues in each TMD). Amino acids in the vicinity of this residue 
will be numbered in relation to this locus (i. e. the preceding residue would be 3.49 
while the following residue is assigned to be 3.51). The original number specific for 
each receptor will follow the general number in brackets (see Figure 3). This combined 
numbering system simplifies the comparison of amino acid residues between related 
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Ligand binding in GPCRs 
GPCRs rt:spond 10 a variety of stimuli \'11I)'iog from pho' DOs.. small cations and 
catccholamincs.. ollCkotidcs and neurolrdJIsmillers through ~ptidcs and protcascs 10 
large gl)'wprotcins and phospholipids (reviewed in rt'f. [15. L8. 391). [n ~C'nl years II 
greal deal haJ bc;:-n lcaml about ligand bir1ding and receptor activation by mutagenesis 
studies. 
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interact with multiple loci. A decreased binding affinity due to a mutation can also be 
caused by a change in configuration of either the ligand or the receptor. 
Comparative studies of related GPCRs and computer modelling programs have been a 
great help in modelling GPCRs and identifying the ligand-binding pocket [9, 23]. By 
comparing related receptors, similar residues can be identified which help in the 
assembly of computer models. Fitting the ligand into the simulated receptor model, 
putative points of interaction can be identified. Adding new experimental data, these 
models may then be refined. This might help to make more accurate predictions about 
the nature and size of the ligand binding pocket. Even in the absence of a model at the 
molecular level a fairly accurate model may be drawn up. These models will improve as 
more experimental data are added although precise judgements of distances and 
orientations of side chains will only be possible when the crystal structure of a GPCR is 
obtained. This however will still not be enough as the crystal structure of a GPCR will 
freeze the receptor in a certain conformation. To make an accurate description of the 
movements of domains during receptor activation, the crystal structure of a number of 
different conformations of a GPCR needs to be obtained. Until then computer based 
models will be the closest estimate of the 3D structure of GPCRs. To construct models, 
however, experimental data obtained from a big range of receptors will be taken. This 
might have the limitation that each receptor might have its own defined micro-
environments, which may vary from receptor to receptor, thereby distorting the overall 
model. 
Non-peptide and small peptide ligands are thought to bind entirely within the 
transmembrane spanning domain, while many larger peptide ligands appear to bind 
partly to extracellular domains and to extracellular boundaries of TMDs (reviewed in 
ref. [16, 18,39]). Large glycoprotein hormones bind predominantly to the extracellular 
domains [16, 18,39]. There seems to be a correlation between the size of the ligand and 
the size of the N-terminus with the exception of neurotransmitter receptors, such as the 
Ca2+_, glutamate- and thrombin receptors [18]. Although these family C type receptors 
bind small ligands they were found to possess very long N-terminal domains which are 
believed to bind the ligand and then interact with the TMDs to activate the receptor 
[18]. While receptors binding large glycoprotein hormones have N-termini of up to 
-400 residues, adrenoceptors have N-termini 7 to 30 amino acids in length [17]. 
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Although this suggests an involvement of the N-terminus in ligand binding for large 
ligands, there is little evidence for its involvement in binding smaller peptides. To 
highlight similarities and differences in ligand binding between different receptors that 
bind differently sized ligands, representative receptors are discussed below. 
Ligand binding in amall non-peptide ligand receptors 
Receptors binding biogenic amines are some of the most studied GPCRs. Since 
biogenic amines contain a positive charge it was assumed that there would be a 
negatively charged counter-ion within the ligand-binding site [16, 83]. Aspl.l2(ll3) was 
identified in the p-adrenergic receptor to form a salt bridge with the amine group [83]. 
This residue was found to be conserved in a homologous position in the alA-adrenergic-
[84], Ml-muscarinic-acetylcholine- [85] and histamine H2 receptors [86]. Glu in 
position 3.28(113) was identified in a similar position in rhodopsin. This residue is 
thought to serve as a counter-ion for the Schiff's base that covalently binds retinal in 
TMO-VII. Lys in the ETB-endothelin receptor [87] and in the equivalent position of the 
GnRH receptor [88] is also believed to be involved in ligand binding. Although the 
residue in position 3.32 has an important function in ligand binding, it was shown to 
have no effect on receptor activation in the GnRH receptor, as mutants in this position 
can still be activated properly [88]. This, however, is in contrast to observations in the 
alB-adrenergic receptor, where Aspl.32(113) has been proposed to form a salt bridge with 
Lys7.36(111) that stabilises the receptor in the inactive conformation [89, 90]. Interestingly 
Glyl.16(121), which is found one helical turn further down compared with residue 3.32 
and two helical turns away from Glu1.28(lIl) in rhodopsin, is believed to interact with the 
C9-methyl group ofretinal [91]. 
Adrenoceptors bind catecholamines that contain hydroxyl groups in the para- and meta 
position of the phenol ring. Two Ser residues in position 5.43(204) and 5.46(207) are 
believed to hydrogen bond the meta- and para hydroxyl groups respectively [92]. These 
residues are conserved in all GPCRs that bind catecholamines, i. e. dopamine, a- and 
p-adrenergic receptors (reviewed in ref. [16, 17D. On the other hand, receptors that do 
not bind catecholamines, e. g. the 5-HT2A-receptor, which binds mono-hydroxy-
tryptamine, the muscarinic-acetylcholine- and histamine receptors, all contain different 
residues in these positions [15, 16]. Asp in position 5.42 and Thr in position 5.46 of the 
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histamine receptor are also implicated in binding the immidazol ring of its ligand [86]. 
In the muscarinic-acetylcholine receptor two Thr residues are found in position 5.38 and 
5.42 and this pair is only offset by one helical turn compared with the Aspffbr pair 
found in the histamine receptors. These two Thr residues are also believed to be 
involved in ligand binding by hydrogen bonding the ester moieties of the ligand [93]. It 
can be seen that this part of TMD-V is very important for binding small non-peptide 
ligands, even if receptors bind ligands that are not similar in structure. 
Another residue important in stabilising the catechol ring in adrenoceptors is Phe6.S2(290) 
[94]. This residue is conserved in all GPCRs that bind aromatic biogenic amines [16]. 
M3-muscarinic-acetylcholine receptors, which bind aliphatic amines, contain a Tyr in 
position 6.51. This residue is believed to form a hydrogen bond with the ligand [16]. In 
Rhodopsin, Trp6.48(26S) and Tyr6.S1(268) associate with the ~-ionone ring of retinal [95]. 
This again shows the importance of similar regions in ligand binding for all GPCRs that 
bind small non-peptide ligands. 
Furthermore, computer models suggested an involvement of Asn6.SS(293) in binding the 
~OH group of agonists of the Pl-Bdemergic receptor. Mutation of this residue to Leu 
resulted in a receptor with reduced stereo-specificity for agonists indicating a possible 
involvement of this residue in forming a hydrogen bond with the ~-OH group of the 
ligand [96, 97]. 
To date, all residues identified to be involved in ligand binding in the adrenoceptors are 
conserved amongst all adrenergic receptor subtypes [16, 17]. To explain the differences 
in pharmacology, one has to look for non-conserved residues. Chimeric exchange of the 
~I- and Pl type adrenergic receptors identified the region from TMD-IV to TMD-V to 
confer different affinities for certain ligands [98]. No single residue could be identified 
for being responsible for this phenomenon. It is likely that there are a number of 
residues involved, and/or the tertiary structure also contributing to the differences in 
pharmacology. This is a problem often encountered, as most interactions are not straight 
one on one, but rather involve more than one residue. Not much progress has been made 
in fine-tuning the ligand binding site, which is made even more difficult by the absence 
of structural information at the atomic level. 
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Ligand binding In peptide receptors 
In two-dimensional studies a loss in binding affinity might be caused by two events. 
Firstly a receptor-ligand interaction might be affected by a mutation, and secondly an 
intra-molecular interaction might be disrupted by changing the configuration of the 
ligand binding pocket thereby preventing the ligand from entering. Peptide ligands are 
variable in size ranging from three residues to more than 50. As the size of the ligand 
increases, the possibilities for interaction with the receptor also increase. Not only are 
there a greater number of potential points of interaction, but the conformation of the 
ligand may also affect binding affinity as seen in the GnRH receptor [99]. By mutating 
a residue of the ligand, its overall structure might be altered rendering the ligand 
incapable of interacting with receptor binding sites. Analysis of interactions between a 
receptor and a large ligand may therefore be more. difficult than the analysis of 
interactions between a receptor and a small ligand. Interpreting whether ligand binding 
was influenced due to a direct interaction being lost or due to an indirect effect (e. g. by 
a change in the ligand binding pocket or a change in structure of the ligand) is therefore 
a challenging task, especially for receptors binding larger ligands. 
As ligand size increases exclusive binding within the transmembrane bundle is no 
longer feasible and interactions with the extracellular domains become paramount. The 
structure of extracellular domains is uncertain, as it is assumed that these domains could 
be in a number of different conformations (e. g. a-helix, ~sheet or random coil). Due to 
a vast difference in length and amino acid composition of extracellular domains, it is 
challenging to compare results from experiments obtained in different receptors. Thus, 
few advances have been made in attempts to model the extracellular domains, which 
further complicates identifying ligand binding mechanisms of larger ligands. Like small 
non-peptide ligands, small peptide ligands, however, are believed to bind within the 
transmembrane domains, while larger peptide ligands are believed to bind to both, the 
superficial parts of the TMDs, and to the extracellular domains [15, 16, 18]. Below, two 
representative examples are discussed: the Thyrotropin-Releasing-Hormone (TRH) 
receptor, which binds a tripeptide, and the AT.-angiotensin II receptor, which binds an 
octapeptide. 
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Four contact points of TRH (pGlu-His-ProNH2) have been identified within the 
transmembrane bundle of the TRH receptor. Arg7.J9(J06) in TMD-VII is thought to 
directly interact with the terminal carboxamide [100], while T~·JJ(I06) and AsnJ·J7(1I0) 
in TMD-III are believed to interact with pyroGlul by hydrogen bonding [101, 102]. 
Tyr6.SI(282) in TMD-VI was suggested to interact with Hi~ [100]. 
In the AT I-angiotensin II receptor, LysS.42(199) in TMD-V has been indicated to interact 
with the a-carboxy group ofPhe8 [31, 103, 104]. This interaction is made possible by 
the interaction of His6.SI(2S6) in TMD-VI with Phe8, which is likely to be responsible for 
the proper positioning of the a-carboxy group [104]. Arg2 is believed to form a second 
salt bridge with ASp7.J2(281) in EL-3 [105] while AsnJ·JS(III) in TMD-III is thought to 
interact with Tyr4 [106]. The latter interaction presents is thought to present the first 
step in receptor activation [107] and will be discussed in more detail under Activation of 
GPCRs. Weak interactions were also shown between Hiss.26(18J) in EL-2 and Aspl [lOS]. 
As mentioned earlier, an important parameter amongst larger peptide ligands is their 
conformation. Angiotensin II is proposed to form a horseshoe-like shape, stabilised by a 
salt bridge between the terminal amino- and carboxy-groups. This structure is also 
predicted for other peptide ligands such as. GnRH, which is a decapeptide (discussed 
below). 
The above findings indicate that the binding pocket of peptide ligands is very similar to 
that of small non-peptide ligands (Table 1). Especially residues 6.51 (for the TRH-, 
muscarinic-acetylcholine- and ATI-angiotensin II receptor) and 6.52 (for the 
adrenergic-, 5-HT2A- and histamine receptors) seem to be involved in ligand binding for 
these classes of GPCRs. It is not clear in many receptors whether residues interact 
directly with the ligand or whether these residues only influence the overall structure of 
the ligand-binding pocket. Furthermore, both TRH and angiotensin II seem to bind to 
their receptors in a similar region as ASpJ·J2 of the biogenic amine receptors. Although 
no contact ofTRH was identified in TMD-V, the 5.42 interaction, similar to the ones 
observed in the adrenergic-, histamine-, and muscarinic-acetylcholine receptors, has 
been identified in the ATI-angiotensin II receptor [103, 104]. Contrary to the small 
non-peptide ligand receptors, TMD-VII, or the boundary of TMD-VII and EL-3, has 
also been shown to be involved in ligand binding in both the TRH- (discussed below) 
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and ATI-angiotensin II receptor [105]. Although there are small changes to the ligand 
binding pocket in each receptor, a general theme for ligand binding is observed which, 
is independent of the nature of the ligand (Table 1). 





ASp3.» Asp3.32 ASp3.32 Tyr,33 Lys3.32 m Gly3.36 Asn3.3' Asn3.3S 
EL-Z TyrS28. HisS26 
'Thr'.SII 
TMJ).. Tht'.42 AspS,42 W,43 Lys',42 
V 'Ibi-',46 W,46 
TMD- Trpo .... 
VI Tyr6.'J Tyr6,SJ Phe6.'2 Phe6,'2 Tyr6,SJ His6.SJ 
EW Asn6.,.. Asp',32 Asp',32 
TMD- LYS7.43 Arg',39 VII 
Table 1: Comparison of binding sites of rhodopsin and the muscarinic-. histidine, adrenergic, TRH, 
angiotensin 11- and GnRH receptor. Residues are numbered according to Ballesteros and 
Weinstein (see text and [9]), Contact sites between the ligand and the receptor are mainly 
conserved in TMD-m, TMD-V and TMD-VI even across receptors with different ligands. It is 
interesting to note that ELs have only been implicated in binding of peptide- or glycoprotein 
receptors so far. There is a dispute about whether TRH interacts with residues in TMD-D or 
TMD-m (.). These interactions, however, indicate that TRH might interact with the 
extracellular loop domains prior to its insertion into its ligand binding pocket. A similar 
mechanism where the loops guide the small ligand into its binding pocket might also be 
employed by biogenic amine receptors. 
TRH therefore seems to be embedded in the transmembrane bundle without making any 
contact with the extracellular domains. This might be due to its small size. Larger 
peptide ligands often make contact with at least one residue in the extracellular 
domains, as seen with the Asp',32(28ItAri interaction of the AT I-angiotensin II receptor 
with its ligand. This may position the ligand properly for binding to take place (also see 
discussion on ligand binding of the GnRH receptor). More recent experiments have 
shown an interaction between pyroGlul ofTRH and Tyr,·28(181) in EL-2 [108]. EL-3 has 
also been implicated in binding TRH [109, 110]. The extracellular domains are 
proposed to form a channel that facilitates the entry of the ligand into the 
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transmembrane bundle by low frequency fluctuations [108]. This interaction is believed 
to happen prior to the insertion of the ligand into the binding pocket as it is sterieally not 
possible for pyroGlul to simultaneously interact with Ty~·33(106), Asn3.37(1I0) and 
Tyr'·lI(lll) [108]. It has been proposed that this might be a model for all receptors that 
bind small ligands [108]. More evidence has to be obtained to establish whether the ELs 
are part of the binding pocket or whether they guide the ligand into it. It remains to be 
seen whether this mechanism is applied by other receptors than the TRH receptor. 
Ligand binding In glycoprotein receptors 
Glycoprotein receptors are different from other members of the rhodopsin-like family of 
GPCRs in having a long N-terminus roughly the same size as the rest of the receptor. 
The long N-terminus most probably evolved to bind these large heterodimeric ligands. 
These receptors consist of two distinct domains that can be expressed individually 
(reviewed in ref. [111, 112]). The N-terminus, or exodomain, containing the high 
affinity hormone-binding domain, is glycosylated with sialic acid but cannot generate a 
signal. The rest of the receptor, the endodomain, is very similar in size and nature to all 
other GPCRs and is responsible for relaying the signal to the heteromeric G proteins. 
This part of the receptor cannot bind the ligand with high affinity [111, 112]. The ligand 
generally consists of two subunits: an a-subunit, common for all ligands, and a 
~-subunit, which is specific for each receptor. Although the a-subunit is conserved, it 
may function mainly in ligand binding in some, and mainly in receptor activation in 
other receptors [111]. Despite its size, very few residues of the N-terminus are proposed 
to interact with the ligand. For the LHlhCG receptor the N-terminus is proposed to be iD 
a horseshoe-like shape that lies flat on the surface of the endodomain, contacting several 
residues. The ligand is guided into the horseshoe, maybe by some low affinity 
interactions with the endodomain, where residues of the receptor insert into a groove 
between the two subunits of the heterodimer ligand [111]. The remainder of the ligand 
is found in the space between the two arms of the horseshoe, making few, if any, 
specific interactions. The insertion of residues into the groove triggers a structural 
change in the ligand that is potentiated by the oligosaccharides of the ligand pushing 
against the arms of the horseshoe, forcing a structural change of the exodomainlligand 
complex [Ill]. A secondary low affinity contact is made between the ligand and the 
endodomain, which in tum forces a conformational change in the latter part, eventually 
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relaying the signal to the G proteins [111]. Although the ligands consist of two subunits 
and are considerably larger in size, it is believed that the general mechanism underlying 
receptor activation is similar to the mechanism in other GPCRs [111]. The large 
exodomain might function as an adapter to facilitate binding of a large ligand to a small 
receptor, either acting more as a ligand itself or by guiding the large ligand into the 
correct position. Further experiments are needed to identify residues involved in ligand 
binding and receptor activation, so that this group of GPCRs can be compared better 
with other members of the GPCR family. 
Activation of GPCRs 
Background 
Although considerable information has been obtained on the ligand binding pocket and 
ligand interaction sites of GPCRs, there is less knowledge on the molecular mechanisms 
mediating activation of GPCRs. Ligand binding and receptor activation are often 
difficult to separate. Receptor activation, however, is likely to be independent from the 
ligand binding [15], as seen in rhodopsin where the ligand (11-cis retinal) is covalently 
bound to the receptor as an inverse agonist. Furthermore there is a number of receptors 
which have been shown to be constitutively active [113-115] or produce elevated levels 
of secondary messengers upon overexpression [116-119]. Upon isomerisation to all-
trans retinal by a photon, the ligand is converted from an inverse agonist to an agonist. 
As both forms of the ligand are covalently bound to the receptor, this shows that ligand 
binding might not be crucial for receptor activation. 
Conformational changes of the transmembrane helix bundle are proposed to be involved 
in the activation and inactivation of the receptor through a network of interactions 
between residue side chains. It is believed that there is an equilibrium between the 
inactive (R) and active (R·) conformation of GPCRs [117,118]. The level of basal 
receptor activity is dependent on the equilibrium between R and R·. In the absence of 
ligand the equilibrium is generally shifted towards R and secondary response is at low 
basal levels [18, 118]. Agonists are defined as ligands that bind to and stabilise the 
receptor in the R· conformation. Furthermore certain mutations of the receptor may 
destabilise R, or stabilise R· leading to constitutive activity in the absence of agonist 
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[113-115]. These mutations have been found in almost every domain of GPCRs 
(references can be found in [IS]). Inverse agonists bind to and stabilise the receptor in 
the R conformation, while antagonists bind equally well to the active and inactive form 
of the receptor [1I7, 1I8]. 
The above model, however, has been challenged by Noda et al who propose that the 
AT lA-angiotensin II receptor must pass through a partially active (R') state to become 
activated [106]. A similar model has also been proposed by Gether and Kobilka [120]. 
Noda and co-workers argue that two residues (residues 4 and 8) of the octapeptide 
angiotensin II are responsible for the conversion of R to R'. In support of this model the 
authors identified a constitutively active receptor mutant which in their model 
represents R'. Asn3.35(III)was suggested to form an interaction with Tyr7.43(292) [107] 
and/or Asn7.46(295) [121] constraining the receptor in an inactive state. This interaction 
has to be broken for the receptor to become activated. Residues 4 and 8 of angiotensin II 
are involved in the initial conversion of the receptor from R to R' [106] by breaking the 
bond between Asn3.35(1l1) and Tyr7.43(292) or Asn7.46(295). Tyr7.43(292) is now free to bind to 
Asp2.5O(74) [122]. If Tyr in position 4 and Phe in position 8 of angiotensin II are 
substituted, the receptor cannot assume R' and thus cannot be activated [106, 123]. As 
the constitutively activated receptor mutant is already in the R' conformation, Tyr and 
Phe in position 4 and 8 of angiotensin II are not required for receptor activation of the 
mutant receptor [106]. A model for receptor activation involving more than two 
receptor states has also been proposed by other groups [15, 124.128]. 
The breaking of a salt bridge, which stabilises the inactive state of a receptor has also 
been identified in being the initial step in receptor activation in rhodopsin [95] and in 
the alB-adrenergic receptors [89, 90]. In rhodopsin, Glu3.28(1I3) and Lys7.43(296) are 
proposed to form a salt bridge that is broken during the initial stage of receptor 
activation [95]. A similar function has been assigned to the ion pair ASp3.32(125) and 
Lys7.36(331) of the alB -adrenergic receptor [89, 90]. It seems to be a common theme 
having a salt bridge between TMD-III and TMO-VII that stabilises the inactive state of 
the receptor. All residues identified to participate in these salt bridges are on the same 
face of the helix. GPCRs might therefore have a common mechanism of receptor 
activation, at least in the initial stages. Residues participating in these salt bridges are 
found closer to the cell surface compared with the rest of the receptor activation 
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machinery (discussed below) and might be in direct contact with the ligand, thereby 
initiating receptor activation. Whether receptor activation involving an intermediate R' 
state is a general phenomenon for all GPCRs remains to be shown. It also remains 
unclear whether receptor activation is ligand induced (as in Noda's model and 
rhodopsin) or whether a secondary response is triggered by conformational selection of 
R· by the agonist. 
The events linking ligand binding and receptor activation are unclear at present. The 
possibility exists that residues might have multiple tasks in receptor functioning. 
Whether residues serve only one or multiple functions, e. g. ligand binding, receptor 
activation, G protein coupling and G protein activation cannot be dissected easily. It is 
often difficult to distinguish from experimental data whether a residue mutated is 
involved in receptor activation and receptor coupling, or whether the mutation only 
affect one of these properties. Mutations of multitask residues would therefore change 
more than one function. If these functions involved different residues, mutations would 
only affect one, while the other functions might still remain intact. It would be 
advantageous though if different events were guided by residues that are at least in close 
proximity. Close proximity would also ensure that even subtle changes could trigger the 
. necessary response. The further away these residues are the more complex the 
mechanism that links the two events becomes. It would therefore be of benefit for the 
receptor if some residues had multiple tasks, or if residues involved in the different 
mechanisms were at least in close proximity. For GPCRs with small ligands the agonist 
binding site can be in close proximity to residues involved in receptor activation. 
GPCRs with peptide and glycoprotein ligands, however, have evolved away from this 
model. The process linking ligand binding and receptor activation becomes more 
complicated when effector residues are far away from each other, and requires a 
network of interactions to trigger a response distal to the stimulus. It can be seen, 
however, that there might be important axis connecting residues involved in different 
functions of the receptors. This axis, however, would provide a mechanism to further 
fme-tune the action of different ligands. The possibility exists that in some receptors the 
ligand binding pocket is forced to be in a low affinity state for agonists by a network of 
interactions that lock the receptor in its inactive conformation. By mutating the axis that 
connects the ligand binding pocket and the residues for receptor activation, the binding 
pocket can become more independent of the receptor activation machinery. Likewise, 
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G proteins cannot be activated when this axis is broken, even when an agonist occupies 
the binding pocket. With the binding pocket more independent of the receptor activation 
machinery, it could assume a conformation thermodynamically more stable for this 
microenvironment, which explains that uncoupling may be associated with increased 
agonist affinity as reported by Parent et al [129]. On the other hand a constitutively 
active mutant does not necessarily have to show increased binding affinities for agonists 
as observed by Cho et al [130]. Although the receptor is in a partially activated state, it 
might be thermodynamically favourable for the binding pocket to remain in a low 
affinity state for agonists. Upon agonist binding the receptor could then become fully 
active and the G proteins would be activated through a mechanism which involved other 
residues than the mutated one as seen by Noda et al [106]. Because of the huge network 
of interactions it is unlikely that any process involves only one residue. Mutating a 
residue involved in such an axis would thus often result in an intermediate between two 
conformational states. 
The precise molecular mechanisms involved in the conversion of receptors between the 
different states are largely unknown. It is believed that the activation of GPCRs is 
caused by a conformational change in the arrangement of the TMDs through rotation 
and/or by changing the network of interactions of TMDs involved, which in turn 
changes the three-dimensional arrangement of the intracellular loop domains [34, 131]. 
This process allows a cognate G protein to bind to portions of the intracellular loop, 
which previously had not been accessible. 
As TMD-III, TMO-V and TMD-VI are important for agonist binding in most GPCRs of 
the rhodopsin family, they are likely to playa role in receptor activation. Indeed 
TMD-III, containing the counter-ion for the biogenic amines, seems to be the major 
contributor in receptor activation (discussed below). IL-3, which connects TMD-V and 
TMO-VI, has also been implicated in coupling to G proteins in a number of receptors 
(reviewed in ref. [17, 40]). The involvement of TMD-III and TMD-VI in the 
rearrangement of the transmembrane bundle during receptor activation was also 
highlighted by spin labelling studies of rhodopsin [132, 133]. Further support of this 
theory was derived from experiments where free cysteines were labelled with a 
fluorescent dye in the ~-adrenergic receptor [15, 33, 134, 135] or exposed to sulfhydryl 
reactive agents [114, 136]. UV absorbance ofTrp and Tyr residues was used as another 
32 
tool to show the involvement of TMD-Ill and TMD-VI in receptor activation [137]. 
Finally the creation of Zn2+ binding sites also hinted towards a movement at the 
TMD-IIIIfMD-VI interface during receptor activation. When residues in TMD-lII and 
TMD-VI were mutated in rhodopsin, a Zn2+ binding site was created. Upon Zn2+ 
binding the receptor could not be activated which was attributed to the incapability of 
the TMDs to change the orientation relative to each other due to the binding of Zn2+ 
[138]. Movement of other TMDs is also possible but has yet to be shown [15, 120]. As 
the above findings were carried out in different GPCRs, these results provide further 
evidence that mechanisms underlying ligand binding and receptor activation might be 
conserved amongst the GPCR family. 
Due to the difficulty of obtaining crystal structures of GPCRs alternative approaches 
have been employed to delineate the different conformations of GPCRs. Experiments 
where receptors have been mutated to constitutively active receptors and/or convert 
antagonists to partial or full agonists, have shed some light on the process of receptor 
activation (e. g. [106, 124]). Other experiments have identified microdomains that 
examine residues that are likely to be in close three-dimensional proximity and involved 
in receptor activation, i. e. stabilisation of the active conformation [34, 37, 139]. 
The DR motif at the cytosoUc end of TMD-III 
As GPCRs are assumed to have a very similar overall structure, it is believed that the 
mechanisms underlying receptor activation are conserved. Residues involved in 
receptor activation should therefore be conserved throughout the GPCR family. The 
most highly conserved amino acid amongst rhodopsin-family GPCRs is an Arg at the 
intracellular end of TMD-III, which is found within a highly conserved 
(IlL )xxDRxxx(IN) motif. It has been shown in rhodopsin [140, 141], adrenergic- [36, 
94, 124], muscarinic-acetylcholine- [142, 143], 5-HT7- [144], V2-vasopressin- [145], 
histamine H2- [146] and GnRH receptors [34, 147] that this Ary}'so is essential for 
receptor coupling. In all these receptors mutation of this residue severely impairs or 
completely abolishes signalling in response to agonists. However, when this residue was 
mutated in the a IB-adrenergic receptor only mutations to Glu, lie, Asn and Ala 
completely abolished a secondary messenger response [36]. Although IP production of 
the Arg3.'0(1431iis and Arg3.5O(143) Asp mutants were impaired, they had an increased 
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basal IP production while the Arg3.SO(I43>tys mutant was even more constitutively active 
and supercoupled [36]. Similarly, in the oxytocin receptor the Ar-r·SO(I37)Ala mutation 
also gave rise to a constitutively active mutant receptor [148]. Although there was a 50-
fold loss in potency, the mutant receptor was still able to produce a maximal IP 
response [148]. These two receptors clearly do not require Arg in position 3.50 to 
produce a secondary messenger response, which indicates that Arg3.SO is not directly 
involved in G protein activation. Arg3.SO is therefore more likely to act by changing the 
overall conformation of the receptor from the inactive to the active state. Since Arg3.S0 
was only mutated to very few different residues in most studies, a more thorough 
investigation of the requirements of this side-chain will be important to elucidate the 
mechanisms underlying receptor activation in more detail. 
The Asp residue immediately preceding ArIf'so also seems to have an important 
function in receptor activation. When this residue is mutated the resultant receptor is 
often constitutively active [114, 131, 146, 149-151] or supercoupled [34, 124, 147, 
152]. It was also shown that mutation of Asp3.49 in the Jh-adrenergic receptor changed 
the orientation ofTMD-VI, adding further support to the involvement of this residue in 
the process of receptor activation [114]. In rhodopsin, the protonation of Glu in the 
homologous position has been shown to be a major step in the initial stages of receptor 
activation [153]. Despite this finding, it is unlikely that the charge of Asp3.49 is the only 
driving force for keeping the receptor in the inactive state. Substitution of this residue in 
the alB-adrenergic receptor by any of the naturally occurring amino acids renders the 
receptor constitutively active [131]. Basal IP levels increased by 18 to almost 7000A. 
compared with basal IP levels of the wild-type receptor. These mutants also retain their 
response to agonists, showing that these mutant receptors are supercoupled rather than 
just constitutively active. Mutations of Asp3.49 to Asn, a neutral side chain, and to Arg, a 
positively charged side chain, in the alB-adrenergic receptor result in much lower 
constitutive activity than replacement of this residue by an Ala or Thr [124, 131]. There 
is, however, a trend with the degree of activation decreasing as constitutive activity 
increases [131]. Other groups, however, found that mutations in this locus decrease or 
completely abolish signalling in other GPCRs, but this observation was sometimes 
made in combination with almost undetectable receptor expression [85, 154]. Because 
of different microenvironments in the various receptors, the effects of mutating this 
residue might differ amongst the different receptors. As the majority of reports of 
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mutations of Asp3.49 result in supercoupled or constitutively active receptors, it is likely 
that Asp3.49 stabilises the inactive conformation of GPCRs [34]. 
Ile or Val in position 3.54 of the (IlL )xxDRxxx(IN) motif has been proposed to form 
part of a hydrophobic cage as a large hydrophobic side chain is needed in this position 
for signalling to occur [34]. It has been proposed that Arg3.SO interacts with Asp3.49 in 
the inactive conformation [34]. Upon protonation of the latter residue, Ar~·50 is 
released. The bulky side-chain of residue 3.54 is positioned in a manner which restricts 
the movement of the Arg side chain, preventing it from dipping into the cytosol. The 
Arg3.50 side chain is therefore restricted to move within the transmembrane bundle, 
ultimately turning TMD-III starting the process of receptor activation [34]. Data from 
experiments mutating IlelLeu in position 3.46 indicate that although this residue is very 
conserved amongst GPCRs, it is not involved in receptor activation [34]. 
CORserved TMD-IIITMD-Vllloci 
Other highly conserved motifs in GPCRs are an Asp residue in TMD-II (Asp2.,,) and an 
Asn in TMD-VII (Asn7.49). The discovery that these two residues are interchanged in 
mammalian GnRH receptors [139] has sparked experiments where either one or both of 
these residues have been mutated. A summary of single and double 2.50n.49 mutations 
(Asp to Asn and Asp to Asn) can be seen in Table 2. In most cases if Asp2.so is mutated 
(to Asn or Ala), the secondary messenger response is markedly impaired [84, 85, 148, 
155-166] and a change in agonist affmity is observed [84, 148, 157, 158, 160, 163, 164, 
166, 167]. Signalling, or in some cases binding, can be rescued, however, by 
simultaneously mutating Asn7.49 to an Asp, resulting in a reciprocal mutant receptor 
mimicking the motif found in mammalian GnRH receptors [155, 158, 160, 162]. This 
shows that these two residues might be in close spatial proximity and indicates the 
requirement for at least one Asp residue in either of the locations for signalling to take 
place. It is assumed that these two residues are in the immediate vicinity and form a 
network of hydrogen bonds in this region essential for proper functioning of GPCRs 
[34]. Asn residues in both loci are generally tolerated but result in receptors which bind 
ligands with the secondary messenger response severely impaired [37, 84, 155, 156, 
158-160, 162, 168]. Two Asp residues in these positions gave inconsistent results with 
some of the receptors not being expressed [37, 139, 160] while others showed normal 
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ligand binding properties [155, 158, 162, 165, 166] and even coupling [158, 162, 165, 
167]. Some Asn7.49 Asp mutants, however, are supercoupled [155, 166]. It is assumed 
that one of the two Asp residues has to be protonated for hydrogen bonding to occur in 
order to prevent repulsion of the two negative charges and to obtain a hydrogen bond 
donor as ionic Asp side chains can only function as hydrogen bond acceptors [34]. The 
above findings show that a very specific conformation of these two side chains is 
needed for receptor activation, with one negative charge and a network of hydrogen 
bonding being essential. This is further highlighted by the fmding that, as opposed to 
Asn7.49 Asp mutations, Asn7.49 Ala mutations in the 5-HT2A- [155], ~-adrenergic- [166], 
ATI-angiotensin 11- [169], TRH- [158], Tachykinin-NK2- [162], CCKa- [170] and 
Platelet-Activating-Factor (PAF) [129] receptors result in uncoupling, while the 
receptors maintain high expression levels. This indicates that the hydrogen bonding 
between the 2.50 and 7.49 loci is only important for receptor activation but not for the 
structural integrity of GPCRs. The exact configuration of these microdomains, however, 
is dictated by the overall structure of each individual GPCR, which often has its own 
specific requirements. 
The other two residues, which are found in the polar pocket in close proximity to the 
2.5017.49 locus, are the highly conserved Asnl.'O and Tyr7.'3. The role of Asnl.5O in 
G protein coupling seems unclear as mutations of this locus generally result in receptors 
that are poorly expressed [37, 162]. Perlman et al report that mutation of Asnl.5O Asp in 
the TRH receptor causes low expression with normal binding affinity being retained 
while G protein coupling is impaired [158]. Similar results were obtained for the 
Asnl-'O Ala mutant [158]. The above observations lead the authors to conclude that 
residue 1.50 is involved in maintaining the structural integrity of the receptor mther than 
being involved in receptor activation [37, 158]. Scheer et al, however, argue that this 
residue constrains the receptor in its inactive configuration in the alB-adrenergic 
receptor as mutation of this residue to an Asp or Glu result in the receptor becoming 
constitutively active [131]. These observations indicate that the role of Asn l.5O might be 
primarily in maintaining the structural integrity of the receptor by hydrogen bonding to 
residues 2.50 and 7.49 rather than being directly involved in G protein coupling [37]. 
Tyr7.'3 also seems to be important in receptor activation but not in receptor expression 
as receptor mutation of this residue to Phe in the ~-adrenergic receptor gave rise to 
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uncoupling [166]. It was shown in the ATt-angiotensin 11- [122, 169], 'h-adrenergic-
[166, 171] and GnRH receptors [168] that mutating Tyr7.S3 to Ala uncouples the 
receptor as well. From computer modelling of the alA-adrenergic receptor, Tyr7.S3 has 
been proposed to form hydrogen bonds with Thr6.36(29S) and Ser7.S6(3S2) at the 
intracellular end of TMD-VI and at the beginning of the C-terminal tail [124]. More 
recently, by modelling the 5-HT2A-receptor Konvicka et al have implicated the 
conserved NP motif in TMD-VII as an important, highly flexible hinge that allows 
receptor activation [32]. In this model, Tyr7.S3 hydrogen bonds to the carbonyl group of 
residue 7.47 on the backbone of the helix, thereby stabilising the regions above and 
below the binge [32]. Both the above models have been built on computer modelling 
data rather than experimental data. However, there is an agreement that Tyr7.S3 is 
important for maintaining the receptor in a certain configuration rather than having a 
direct function in G protein coupling. Arora et al showed that in the GnRH receptors a 
substitution of Tyr7.S3 by Phe is tolerated [168], indicating that the aromatic nature of 
the side chain and not the hydroxyl group ofTyr7.s3 is important for receptor activation. 
The GnRH receptors, however, form an exception by having an Asp in position 7.49. 
This indicates that the overall configuration of the binge might be slightly different to 
the majority of GPCRs that have an Asn in this position. It was furthermore shown that 
Phe substitution of Tyr7.S3 in the Pl-adrenergic receptor partially uncouples the receptor 
[166]. Slice et al reported that the Tyr7.S4 Ala mutation neither influenced coupling, nor 
did it influence agonist binding, intemalisation or sequestration in the GRP receptor 
[172]. This receptor, however, has three residues between Prouo and the Tyr in the 
conserved NPX2-3 Y motif. It may therefore behave differently compared with other 
receptors containing two rather than three residues between Pro7.SO and the Tyr, as it is 
likely that the Tyr side chain points into a different direction. Further experiments are 
necessary to strengthen any of the above models. A direct involvement of Tyr7.S3 with 
the 2.5017.49 and/or 3.49/3.50 loci, however, has yet to be shown although they are in 
close proximity. 
wt DD NN ND DN 
receptor 2.50 7.49 Expr Ag ReSmax ECso Expr Ag Resmax ECso Expr Ag Resmax ECso Expr Ag Resmax ECso 
5-HT2A D N 19% = 95% J, 177% = 0 nJa 43% = 48% J, wt (ref. [155]) 
TRH D N 29% J, 115% J, 235% J, 52% J, 50% J, 115% J, wt (ref. [158]) 
Il-opioid D N 0 nJa nJa nJa 113% J, 2% nJa 90% = 57% J, wt (ref. [160]) 
NK2 D N 62% = 93% nJa 78% = 7% nJa "=" = 57% nJa wt (ref. [162]) 
CCKB D N 77% = 100% nJa 113% = 50% nJa * * * * wt (ref. [165]) 
AngII D N * * * * 50% = 0 nJa * * * * wt (ref. [156]) 
BK D N "=" = 53% = * * * * * * * * wt (ref. [159]) 
Ml-musc D N * * * * 26% = 9% nJa * * * * wt (ref. [85]) 
LH D N * * * * 65% J, 65% J, * * * * wt (ref. [164]) 
PAF D D wt (ref. [129, 157]) * * * * 81% J, 0 nJa 114% = 100 = 
cfGnRH D D wt (ref. [173]) 6% nJa nJa nJa 6% nJa nJa nJa 150% = 50% = 
hGnRH N D 0 nJa nJa nJa 67% = 39010 J, wt (ref. [37, 139]) 29% = 12% J, 
Table 2: Summary of effect of mutations in postions 2.50 and 7.49 in different GPCRs on expression (Expr), agonist binding affmity (Ag), maximal secondary messenger 
response (Resp~ and ECso. • indicates where no references have been found, nla depicts no data available, J. indicates a decrease in affinity or potency, = means 
unchanged affmity while "=" was indicated to be similar to wild-type although no data was shown in the reference. w 
-....l 
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Mechanisms of receptor activation 
Two hypotheses of receptor activation have been brought forward which involve 
residues Asnl."', ASp2."" Arg3."" Asn,·49 and Tyr,·.53 as key players in the mechanism of 
activation. Olivera et al proposed that in the inactive state ASp2.", acts as a counter-ion 
for Arg3 . .50, which moves out of the hydrophilic pocket towards the cytosol upon 
receptor activation [174]. This model has been refined by Scheer et al suggesting that 
ASp3.49 is important in maintaining the receptor in its inactive state. Its protonation 
causes the side chain to move from the outside to the inside of the hydrophilic pocket, 
thereby rotating TMD-Ill. During this process the side chain of Arg3.", is moved out of 
the hydrophilic pocket away from ASp2 . .50 to rest between TMD-VI and TMD-VII, 
ultimately exposing previously buried regions in IL-2 and IL-3 important in coupling 
[35,36, 124, 131]. 
Ballesteros et al, however, argue that Arg3 . .50 interacts with the unprotonated ASp3.49 in 
the inactive receptor [34]. This model is mainly based on the observation that mutant 
receptors at Asp3.49 that are expressed properly generally are constitutively active [114, 
131, 149-151] or supercoupled [34, 124, 147]. Upon protonation of this residue, the side 
chain of Arg3.", moves away from this locus to form an ionic interaction with Asp2.", (or 
Asp,·49 in mammalian GnRH receptors). This process is facilitated by a bulky side chain 
in position 3.54, which prevents the Arg3 . .50 side chain from moving into the cytosol 
[34]. In order to interact with the 2.50 or 7.49 the Arg3.", side chain has to move from its 
original interaction with Asp3.49 thereby rotating TMD-III. This initial movement, which 
has been identified mainly along the TMD-IIIffMD-VI interface [114, 132-136], 
represents the initial stage of receptor activation. 
In view of the latest studies of the ~ . .50 residue, where mutant receptors in this locus 
can give rise to constitutively active receptors [36, 148], both the above models have to 
be refmed. It is essential to gain more information about the special requirements of the 
side-chain of residue 3.50 to understand the mechanism of receptor activation better. In 
most cases Arg3 . .50 plays the pivotal role in receptor activation, but under certain 
conditions Arg3.", can be replaced by Lys, His and even Glu and Ala [36, 148]. 
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In summary it can be seen that there is a considerable amount of data which implicates 
ArgBO in being the heart of the "engine room" of receptor activation. The process of 
receptor activation is started by the protonation of Asp3.49. Joseph et al proposed a 
model of how this proton is relayed from the ligand via different residues down the 
transmembrane helices to Asp3.49 in the AT I-angiotensin II receptor [107]. Other 
GPCRs could have a similar mechanism or share some of the residues involved in this 
relay of the proton. There are a great number of additional residues involved in binding 
and/or activation of G proteins, either through direct interactions or through stabilising a 
certain conformation of the receptor and especially the intracellular domains. Residues 
important for G protein coupling are mainly found in IL-2 and IL-3. Although very little 
homology even amongst closely related GPCRs is found in the regions responsible for 
coupling G proteins, the mechanism of receptor activation seems to be at least partially 
conserved. It has been shown that other residues involved in this process are Asp2.5o, 
Asp3.49, lIeNal3.53 and Asn7.49. In the absence of structural information of GPCRs in the 
active or inactive conformation, it is difficult to propose mechanisms involved in the 
conversion between the two states. More data are needed to shed further light on the 
mechanisms involved and to settle disputes about the orientation and movement of side 
chains during this process. Some of the residues involved in G protein coupling and/or 
activation of the GnRH receptor are reviewed in the GnRH "Receptor activation" 
section. 
The GnRH receptor 
This section of the iotroduction mainly focusts on receptor structure. ligand binding and 
receplOr acth'll1ion of the GnRH rec:eptor. Direcl interactions of GnRH receptors and 
G proteins, inlemalisalioo. dcse:nsilisalion and downrcgulali()fl are nOI the focus of lhis 
thesis and will therefore only be dealt lO.; th where necesSOJ)'. The in tracellular sigualliug 
pathways wi!! also only be mentioned brietly as these: are not pertinent to this thesis and 
are the subject ofexed!cnl rev iew anicles [10. II). 
General Structure 
The first GnRH receptor was cloned from II mouse gonadolrope cell line [Il). The 
structure and sequence of this receptor was confi rmed [175 ) and five other GuRH 
reccplOrs were cloned from mammalian species in quick succession from raL [14. 176· 
178). human [179·181[, sheep [182·184), cow [ ISS1 and pi" (1861. More recently 
non·mammalian GnRH rtteptors. from calfish 13\. goldfish 1·1. 5). frog [6. 7). chicken 
18/ and fruit ni tS {187J. and additional mammalian GnRH rtteptors from marmoset 
1188/. possum [1 891. bonnet monkey [190} and dog 11 911 weTC cloned. Other GnRH 
receptor sequences are available on me Genbank which include receptors cloned from 
three more forms of fish and norse. The GnRl1 receptor is a member of the rhodopsin 
like SUlX'rfamily of GPCRs which illC ludes the families of glycoprotein receptors 
(including FSH. LH/CG and Ih),roid stimulating hormone (TS II) receptors). 
neurotransmiller r«eptors (c.g. adrenergic·. serotonergic·. dopaminergic· and 
muscarinic-acetylcholine receptors). opsiru; and a variet )' of peptide n;ccptoT1l. The 
GnRH rcceptor eonlairu; most of the: characteristics found in this group of receptors 
(Figure 4). mainly eonserved sequences in the TMDs. which also facili tated its cloning 
(I . 10, 192). Mammalian GnRH receptors, howeller. are unique in lacking a cytoplosmie 
C-lCmlinlll tail. having a relatively large IL·I , an apparent interehaQie of residues 2.50 
and 7,49 (AspW(l and AsnHi for most GPCRs, and Alinuo and AspH9 for mammalian 
GnlO! rttCpIOrs). and a SeT or Phe substitution for TyrHI in the conSt!T\'oo DR motive 
in TMD·lll . which is involved in receptor activation (discussed belnw) (figurt' 4. 
reviewed in ref. II. 10. 11 Jl. 
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Like mOSI olher GI'CRs lhe GnRtI receptor contains lWO Cys residues in EL- J and 
EL-2 respeCtively. These 1""0 residues ~re proposed to form 8 disulphidc bond required 
for proper fol ding or llle receptor [193. 194]. II " '115 furthcnnorc proposed lhal lhis 
disulphidc bridge is importan t in swbilising lhe re<:Cplor in the ac tive stale {193]. 
AnathC!" twO Cys residues have been ident ified in lhe N- tcrminus and the C-tcnnina l 
section of ];L·2 of mammuJiPIl GnRH n:cepton;. which are also proposed to form a 






.',~re ~ : Pnmat)' JIIUCCW~ of 1M human GnRtI <I!CC'p''' ' R~d residues ".dalc the mool con>el"N 
'-sid,," In each ~n. )'1110'" m,dur:i .e dlfTm:nt tompIftd with adler GPCRs. blue 
residua lie in.'ol .,..:! in m:epIOI' OCC .... IOII Ind. .. G proIein coupli .. blecL ,esid_ in lipnoJ 
bindkw ond the ....... rnid~ .. !he II>'CQI) taliool alIc. 
T,,'o potential N_glycosylation sites (Asn-X-ScrlThr) ha\'e been identi fied in thcl 
>,J-tcnninus and EL-l of tile cow, pig, sheep and human GnRII receptors. \'0 hilc rodent 
GnRH recepton> have an add itional glycosylalion consensus sequence in the 
N-tcrminus, It was shown tllat only the sitc:s in the N·lc:rminus arc: gl)'cosylntc:d in 
human and mouse: GnRH receptors.. and thai glycosyiation contrib utes to the level of 
receplor expression. This finding was not associated \'oi lh the ItaIlspon of the receptor 10 
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the cell surface. as the nll.lliUlt I'Cceptor did not display abnormal intracellular 
sequestration [451. 
Ligand binding 
Structure and function of GnRH 
To understand the processes involved in ligand binding it is important to have structure-
ac tivity knowledge of the ligand itself. The first mok..;uies ofGnRH " 'erc isolated from 
pig and sheep hypothalami [195. 196]. Two or more (usually three) fomls of GnRH 
have been identified in most vertebrate and portochordate species [197]. Table 3 shows 
all known [omls of GnRH \0 date. GnRH is predominantly expressed in the 
hypothalamus and regu lates the release of gonadotropins from the pituitary. This form 
of GnRH is gellCrally variable between diffe rent spc<:ics /197]. The most ubiquitous 
form of GnRH is GnRH·II. also kno"l1 as chicken GnRH·II or [HisS, Trp7. TyrIJGnRH. 
GnRH-ll has been idcmificd in the eXlra-hypolhalamic areas of the brain of almosl 
evcry venebrnle species f197 J. This fo nn of GnRH was ident ified 10 act as a co-
neurotransmitter in bullfrog [198]. GnRH-JI has also been shown 10 inhibit K+ channels 
in sympathctic ganglia [199. 200]. The question about its function, hov.'Cvcr, remains 
intriguing. especially in view of its complete conservation over a time·span of 500 
million years. 
Although GnRH has been isolated from species spanning o\"cr 500 million >'ears of 
evolution, the length of tile mokcule (a decapeptide) and the N- and C·tcnninw residues 
are eonscn 'ed (Table 3). The most variable PQsition is the residue in position 8. 
followed by position 5 and 7. Residue 6 is Oly in al! higher "ertebrates {I . 197] 
(Table 3). The same fonn ofOnRH has been found in all mammals except thc guinea 
pig [201J. In mammals. mGnRH was found to be much more ac::tive than any other 
naturally occurring foml of GnRH [197]. Since Argl is the only res idue that 
distinguishes mGnRH from any other fonn of GnRH. this residue was identified for 
being critical in high affinity binding of mGnRH to the mammalian GnRH rcceptors 
[197[. In view of the difference between Guinea Pig GnRH and GnRH found in all 
other mammalian species, it "'"QuId be interesting to elOIN: the receptor from th is animal 
as significant changes can be expec ted in its pharmacology. 
Thc following IWO subsccliol1§ summarise: the slruclurc-3clivi ly requirements of each 
amino acid residuc of GnRH. 1llousands of analogues were designed bo;fon: the finil 
GnRJI receplor was cloned. These analogues were therefore only ICSled in \'i\,o or by 
nidio-immunoassays. Two excellenl review nnide:; by Kanen nnd Rivicr [202 1 and b)' 
Sealfon el al [I] summllJ"isc Ihese fi ndings. The informalion used for Ihe IWO 
subsections below was therefore mainly dro\\T1 from these two nnidc!!. unless more up 
to date in vitro information was n;silab lc. which is indicoted in the appropriate places. 
T.bI. J, Primary SlI\Icture ofGnRH. isolllled from p~och<>rdalu and ~~ .... Re$~ ~ ......... -cd 
with m,,,,,malian GnRH are il\llic:atcd by ' . Oiff.".cB! (onm of GJoRH arc rwncd .lkr W 
..,.cieo from ... ~i~h thO)' ""~ first iso~ ""cpl f'" GnRll-U. wflith ~ first idmlirlN in 
chlcl:~n. All GnR H r<>l"Jl\1 .... dccopeplules ... "h a hlocled NH:- and C..JuDIin~ van ..... 
rnid"", are indi<:aL«l by blue bru:co. 
Y) S t ruNure and function or Ih t .-ariable ",gion of GnRJI 
As GnRH-ll is more activc than chielr.en GnRH-I (or IGlnl]GnRH) in 11UUIUlll11ian 
GnRH n:ccptors.. il can be secn that the loss of Argl can be somewhal ~ompc:ru;aled by 
~o-ordinllted substitution of residues 5 and 7 as can be SC<TI by the manunalinn GnRl 1 
receptors having a higher affin ity for GnRH-ll compared with IGln'1GnRH II]. II is 
believed that a neutrnl amino acid in position 8 reduccs biOOing affinity ofGnRH for Ihe 
mammalian fl'(;Cplors. Or1o\:e the GnRIl with a IlCUuaJ amino acid in posilion 8 is bouOO. 
however. il displays impro\"cd efficacy as il shows relalh"cly higher LH-rclcasing 
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potency than [Arg8]GnRH [203]. Contrary to this, His in position 5 seems to enhance 
binding affinity while reducing efficacy [203]. 
Position 5 requires an aromatic side chain but not the hydroxyl group of Tyr for high 
activity in mammalian GnRH receptors. This residue might have an indirect role in 
receptor activation. The third most variable residue of GnRH is position 7. Amino acids 
in this position can be variable with large uncharged amino acids being favoured for 
proper functioning. A basic side chain in position 8, however, is likely to affect the 
ligand structure by stabilising the active form (for mammalian GnRH receptors) by 
hydrogen bonding to the side chains ofHis2 and Tyr'. It has been proposed that mGnRH 
forms a p-II-type bend around residue 6 which is needed for high affmity binding to 
mammalian GnRH receptors but not to non-mammalian GnRH receptors. 
Position 6 is invariably Gly for GnRH molecules of higher vertebrates (Table 3). A 
small side-chain is needed in this position to allow for the P-II-type bend. Not even an 
Ala is tolerated in this position. D-amino acids in this position, however, were often 
found to compensate for the loss of Arg in position 8. When residue 6 is substituted by a 
D-amino acid, the binding affinity of [Gln8]GnRH is increased by about 1000 fold in the 
mammalian GnRH receptors [99, 203]. There is not much change in the affinity of non-
mammalian GnRH receptors for these analogues, indicating that these receptors are less 
sensitive for the conformation of GnRH [203]. Gly and D-amino acids share the ability 
to have positive phi dihedral angles. They therefore more readily allow a P-II-type bend 
at position 6, which is considered to be the active conformation of GnRH at the 
mammalian GnRH receptors. Because of its configuration the side chain of the D-amino 
acid in position 6 faces away from, instead towards, the receptor. Bulky side-chains are 
therefore tolerated when residue 6 is substituted by a D-amino acid. The observation 
that side chains of D-amino acids are facing away from the receptor has been exploited 
for the design of a radio ligand with a D-Tyr in position 6. Besides containing the 
P-I1-type bend, this ligand has the further advantage of being iodinated in position 6 
where the large iodine group cannot interfere with the binding of the molecule [204]. 
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b) Structure and function of the conserved terminal regions ofGnRH 
Both the N- and C-terminal residues of GnRH are extremely conserved amongst all 
forms of GnRH. The N-terminus of GnRH was shown to be involved in both ligand 
binding and receptor activation. This is highlighted by the fact that pyroGlu in 
position 1 is substituted in almost every antagonist synthesised. A requirement in this 
position is that this residue is uncharged. Position 2 requires an aromatic and possibly 
an immidazol moiety, but not an E-position hydrogen bond for activity. His in this 
position is an ideal residue to interact with the receptor. Bul.k.y hydrophobic side-chains 
are generally found in antagonists in this position. The aromatic nature of residue 3 is 
essential for activity of GnRH. This residue seems to be crucial for high potency of 
GnRH in mamma1ian GnRH receptors. Although position 4 is 1000A, conserved amongst 
all naturally occurring forms of GnRH isolated to date, this position is relatively tolerant 
to substitutions. Spatial constraint, however, seems paramount, as no large side chains 
are allowed in this position. 
Contrary to the N-terminus, the C-terminal residues of GnRH are not involved in 
receptor activation but only in binding. Pro in position 9 is believed to constrain the 
conformation of GnRH that is essential for binding. Removal of the amide of GlY-Nlh 
in position 10 results in low activity most probably due to decreased binding affinity, as 
alkyl amines maintain or enhance activity. Small, uncharged moieties are generally 
tolerated while large side chains most probably pose a steric problem during binding. 
It can be seen that no single residue alone is crucial for activity. Figure 5 shows a 
summary of the functional properties of each residue. It should be bome in mind that 
changing a residue might alter either an interaction with the receptor or the 
conformation of the ligand itself, which makes interpretations of two dimensional 
mutagenesis, where amino acid residues in both the receptor and the ligand have been 
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FlaaR 5: Summary of properties of individual residues ofGnRH (as in Sealfon et aI [1]) 
Agonist binding 
Binding sites for GnRH on its cognate receptor, ASp2.61(98) [205], Asn2.6S(I02) [206], 
Lys3.32(121) [88] and ASp,·32(302) [99], have been identified in the extracellular domains 
and close to the extracellular boundaries of the transmembrane domains and are 
conserved in all vertebrate- and non-mammalian GnRH receptors isolated to date [1]. 
Asp2.61(98) bas recently been proposed to hydrogen bond to the o-NH group of Hi~ 
[205]. Furthermore, it has been suggested that ASp2.61(98) hydrogen bonds with the 
backbone NH group ofTrp3 as well as forming an interaction with Lys3.32(121) [205]. It 
was furthermore shown that Lys3.32(121) requires a charge-strengthened hydrogen-
bonding residue for high affinity agonist binding, suggesting an interaction of this locus 
with His2 or pyroGlul [88]. 
Asn2.6S(I02) at the beginning of EL-l has been implicated in an interaction with the 
C-terminal glycinamide [206]. Mutation of Asn2.6S(I02) to Ala had a much greater effect 
on GnRH analogues containing the natural glycinamide moiety compared with the 
effect seen for analogues having an ethylamide at the C-tenninus. It was suggested that 
Asn2.65(102) hydrogen bonds with the C-terminal Gly-amide moiety [206]. 
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In the mouse GnRH receptor, Glu'·32(301) at the end of EL-3 was identified to be 
involved in agonist binding in a study aimed at identifying an interacting residue for 
Argl of mGnRH [99]. Mutations of all acidic residues in the extracellular domains and 
at the superficial regions of the transmembrane domains revealed the importance of 
GIU'·32(301) in the mouse GnRH receptor for selectivity for Argl [99]. The GIU'·32(301)Gln 
mutant had a much lesser effect on [Glnl]GnRH binding than it had on [Argl]GnRH, 
while the affinity for [Glul]GnRH was increased more than 10 fold, adding further 
support to the above hypothesis [99]. Glu'·32(301) is not conserved amongst mammalian 
GnRH receptors. In the human GnRH receptor this residue is conservatively replaced by 
Asp,.32(302). Unpublished results from our laboratory from similar experiments on 
Asp '.32(302) in the human GnRH receptor indicate that this residue has the same function 
as GIU'·32(301) in the mouse receptor. It is believed that this residue is important in the 
initial contact of GnRH with its receptor. 
The above points of interaction have been conserved amongst all cloned GnRH 
receptors, including the non-mammalian ones. As these receptors have very different 
pharmacologies it can be assumed that there are more points of interactions between the 
receptor and the ligands which account for the different specificities unless they are 
entirely due to conformational constraints. 
It can be seen that the binding pocket of the GnRH receptor is at least partially 
conserved with other GPCRs (Table 1). Lys in position 3.32(121) is found in the 
homologous position to the Asp residue which acts as the counter-ion of the amine 
group of small biogenic amines in the adrenergic-, muscarinic-acetyl choline-, 
histamine-, dopamine- and 5-HT2A- receptors. Asp,·32(302) is conserved with the 
AT I-angiotensin II receptor. In both, the AT I-angiotensin 11- and GnRH receptors this 
residue at the end of EL-3 is important for high affinity peptide-agonist binding. It is 
possible that this part of EL-3 evolved to facilitate binding of medium sized peptides 
(about 10 amino acids in size), as this region does not seem important for high affInity 
binding of biogenic amines. The small tripeptide TRH also seems to bind entirely in the 
TMDs, although it has been suggested that EL-3 might provide points of interaction 
[109,110] or at least guides TRH into its binding pockets [108]. 
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The GnRH ligand-binding site seems to be different compared with receptors binding 
small non-peptide ligands in having two contact sites in TMD-II instead of having 
contact sites in TMD-V and/or TMD-VI (Table 1). Neither has TMD-II been implicated 
in ligand binding in the TRH- or ATI-angiotensin II receptor. These receptors, however, 
were shown to have contact sites in TMD-V and/or TMD-VI. TMD-II, however, is in 
close proximity to TMD-III, TMD-VII, and to a certain degree TMD-VI (Figure 2), all 
of which are implicated in ligand binding, indicating that the same might be true for 
TMD-II. Besides in the GnRH receptor, it has been suggested that the Melanocortin-l-
(MCR-l) receptor [207] also contains ligand binding sites in TMD-II. TMD-II contains 
a major constituent of the receptor activation machinery, further highlighting the 
importance of this region for proper receptor functioning. 
Antagonist binding 
Agonists and antagonists are believed to bind to different conformations of the receptor 
(R· and R respectively). It is therefore feasible that the ligand-binding site for agonists 
and antagonists should be at least partly different. Competitive antagonists should have 
an overlapping binding site with the agonist, and therefore compete on the principle of 
volume exclusion. Antagonists may also have a different binding site from that of 
agonists and compete via an allosteric mechanism or conformational selection, binding 
to and stabilising the inactive form of the receptor. An example of this is the 
tachykinin NKI receptor [208]. The majority of GnRH antagonists are peptides, with 
active non-peptide antagonists only being discovered recently [209-211]. The GnRH 
peptide antagonists are generally known to be competitive inhibitors on the basis of 
volume exclusion mechanisms. It was shown that the pre-treatment of pituitary 
membranes with trypsin, chymotrypsin or sulfhydryl blocking agents decreased 
subsequent binding of labelled antagonists. The binding of labelled agonist was 
decreased to a lesser extent indicating that the agonist-binding pocket is less exposed 
and more buried than the antagonist binding pocket [212]. It was also observed that 
mono- and divalent cations had more influence on agonist than on antagonist binding. 
This adds further support to the proposal that the agonist and antagonist binding pocket 
are not necessarily the same [212]. 
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Janovick et al covalently bound photoactive radio labelled agonists and antagonists to 
GnRH receptors [213]. The antagonists and agonists bound to different parts of the 
receptor as shown by different ligand/receptor complexes isolated after trypsin 
treatment. This shows that the photoactive group of the antagonists and agonists are 
exposed to different environments [213]. 
Another indication for a difference in contact sites of the receptor with agonists and 
antagonists came from the study that identified Lys3.32(121) as a point of interaction for 
agonists. Mutation of this 'residue affected agonist but not antagonist binding affinities 
[88]. 
Most antagonists are decapeptides like the agonist. In a number of antagonists mainly 
the N-terminal residues are substituted. It is therefore feasible that the binding site of 
those antagonists and agonists is at least overlapping. Antagonists containing Argl or 
the glycinamide can still bind to Asp7.32(302) and Asn2.65(102), while the N-terminus would 
be able to bind to different loci than the TMD-II contact sites. The recently published 
PAnt-l antagonist ([Ac-D-Lysl, D-4-CI-Phe2, D_Trp3, D_Arg6, D-Ala1olGnRH), was 
shown to have its N-terminus close to residues 11 and 19 of the N-terminus of the 
receptor [214]. Further studies are required to define the antagonist binding pocket more 
specifically. This antagonist binding pocket may, however, vary between different 
antagonists, as points of interactions with the receptor might be different when residues 
are substituted. The knowledge of the exact dimensions of the binding pocket for 
selected antagonists may ultimately lead to the design of orally active non-peptide 
antagonists which could be used in the treatment of a number of hormone dependent 
diseases or as a novel method of contraception for men and women. 
Receptor activation 
As mentioned previously, residues 2.50 and 7.49 are interchanged in the mammalian 
GnRH receptors. Although Asn is found in position 2.50 and Asp in position 7.49, 
GnRH receptors still conform to the model of receptor activation as proposed for other 
GPCRs. Asp in position 7.49 is essential for coupling as a mutation to Asn [37, 139, 
215] or Ala [37] severely impairs secondary messenger response to agonists. When 
Asp7.4S1(311) was substituted by Glu, receptor expression was decreased considerably but 
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coupling efficiency for this mutant still remained at high levels [37]. This indicated the 
necessity of a carboxyl group for efficient coupling to occur. An introduction of an Asp 
or other amino acids in position 2.50 resulted in the receptor not being expressed and 
makes it difficult to identify the role of this residue in receptor activation [37, 139,215]. 
This observation is consistent with results from the fJ.-opioid receptors [160] but is 
opposed to findings in other GPCRs that allow Asp residues in both the 2.50 and 7.49 
loci [155, 158, 162, 167]. This finding is unexpected as the non-mammalian 0nRH 
receptors cloned to date (from catfish [3], goldfish [4, 5], frog [6, 7] and chicken [8]) all 
contain two Asp residues in these positions. This highlights the special evolution of 
mammalian GnRH receptors and shows the importance of other residues in this 
microdomain which are responsible for maintaining the structural integrity of the 
receptor. A reciprocal Asp2.SO(II7) Asn7.49(3111) mutation, however, which mimics the motif 
found in most other GPCRs and the Drosophila 0nRH receptor, restores ligand binding 
[37, 139, 215]. This finding presents further evidence that an acidic and a hydro~en 
bond accepting residue is needed in this microdomain of the receptor for activation to 
occur. Non-mammalian GnRH receptors have two Asp residues in positions 2.50 and 
7.49 which is common to some GPCRs [17]. It is believed, however, that one of these 
residues is protonated in order to form an uncharged hydrogen bond donating side chain 
[34]. Another GPCR where this motif is found is the PAF receptor. This receptor retains 
the coupling function of Asp in position 2.50 as the mutation of this residue to Asn 
results in an uncoupled receptor, while ASp7.49 Asn almost behaves like the wild-type 
receptor [157]. In the non-mammalian GnRH receptor, however, the function of locus 
2.50 in receptor activation is unclear as mutation of this residue in the catfish GnRH 
receptor results in poor expression of the receptor at the cell surface, similar to the 
findings of mutations in the mammalian 0nRH receptors [173]. There is, however, a 
decrease in signalling in response to agonist when ASp7.49 is mutated to Asn in the 
catfish GnRH receptor, indicating that activation of the receptor depends on an Asp in 
this position [173]. The non-mammalian GnRH receptors therefore represent 
intermediates in evolution between the ASp2.,SO Asn7.49 configuration found in most 
GPCRs, and what looks like the ancient form of GnRH receptors isolated from 
Drosophila, and Asn2.,SO Asp 7.49 found in mammalian 0nRH receptors. In non-mammals 
0nRH receptors seems to have already switched the activating function from TMD-II to 
TMD-VII. 
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GnRH receptors couple to the PLC pathway. Interestingly, short-term activation ofPLD 
via small G proteins (ADP-ribosylation factor (ARF) and RhoA) requires an Asn in 
position 7.49 [216]. Since GnRH receptors contain an Asp in this position, they are 
unable to directly couple to the PLD pathway. The reciprocal mutant (ASp2.S0(87) 
Asn7.49(318», however, is able to mediate a PLD response [37], indicating that GnRH 
receptors might have been selected during evolution to prevent coupling to PLD via 
ARFlRhoA rather than PLD. 
Another residue that is not conserved between mammalian GnRH receptors and other 
GPCRs is residue 3.51 of the highly conserved DR motif in TMD-III involved in 
receptor activation. Tyt·S1 found in most GPCRs is substituted by Ser in all mammalian 
GnRH receptors except for the marmoset GnRH receptor where Tyr is replaced by Phe. 
Mutations of Set·S1(140) in the human GnRH receptor to Ala [147] or Tyr [217] did not 
alter expression levels or the ability to produce a secondary messenger response 
consistent with mutations in this locus in other receptors. The set·S1(140)ryr mutation, 
however, changed the rate of internalisation and increased the binding affinity of the 
mutant receptor for GnRH agonist [217]. In the rat GnRH receptor substitution of 
Set·S1(140) by Phe resulted in a receptor where ligand affinity and potency was similar to 
those of the wild-type receptor [188]. The Bmax and the maximal IP response were 
slightly reduced [188]. This indicates that substitution of Ser with Phe reduces receptor 
expression. The rate of intema1isation was increased marginally [188]. Although residue 
3.51 is very conserved amongst GPCRs, this residue is not very conserved as Tyr within 
the GnRH receptor family. The above findings suggest that this amino acid is not 
directly involved in any of the major pharmacological pathways. 
All other residues in the (I/L)xxDRxxx(IN) motif are conserved in the human GnRH 
receptor. Mutations of Asp3.49(138) decrease receptor expression but increase the coupling 
efficiency [34, 147]. This locus is thought to interact with Arg3.5O(139) in the inactive 
state of the receptor [34]. As with most other GPCRs, Arg3.SO(139) is important for 
receptor activation and mutation to Gin [34, 147] leads to uncoupling while mutations 
to His or Lys result in the receptor not being expressed [34]. If mutated, the receptor 
becomes uncoupled. During receptor activation Asp3.49(138) becomes protonated and the 
predicted salt-bridge with Arg3.5O(139) is broken. Arg3.5O(139) might then be guided by the 
highly conserved Ile3.S4(142) to form an ionic interaction with ASp7.49(318), which 
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constitutes the activated receptor and facilitates 0 protein coupling [34]. Mutations of 
Ile3.46(134) showed that this residue is not important in receptor activation or expression 
[34]. 
Other residues involved in 0 protein coupling are Leu3.S8(147) [218, 219], Ala6.29(261) 
[220], Leul.SS(S8) [221], Leu2.36(73) [221], and Tyr7.S3(322) [168]. Leu3.S8(147) is found in 
IL-2 and is conserved in several OPCRs. In the muscarinic-acetylcholine receptors this 
residue has been shown to be involved in 0 protein coupling and receptor sequestration 
[218, 219]. Leu3.S8(147)Ala and Leu3.S8(147)Asp have been shown to have no effect on 
receptor expression levels and affinity for GnRH agonist but severely impaired 
o protein coupling and decreased the rate of intemalisation [217]. It is unclear whether 
this locus is directly involved in 0 protein coupling, or indirectly through stabilising a 
specific conformation of IL~2 needed for coupling or activation of the 0 protein [217]. 
Ala6.29(261) is found in the C-terminal domain of IL-3. Oly and Ser substitutions of this 
locus result in mutant receptors with normal coupling abilities, while Pro and Val 
substitutions give rise to partially uncoupled receptor mutants [220]. Leu, Be, Phe, Olu 
and Lys substitutions give rise to completely uncoupled receptors that retain normal 
ligand binding affinities [220]. Thus the amino acid side chain in this position has to be 
smaller than 40 Da for normal coupling to occur, while side chains of 40-50 Da result in 
partially uncoupled mutant receptors. Receptors containing side chains larger than 
50 Da are completely uncoupled independent of the charge of the side chain. Ala in 
position 6.29 is conserved amongst a great number of OPCRs [17]. Mutation of this 
locus in the aIB-adrenergic- [222], TSH- [223] and LH receptors [224] result in 
constitutively active receptor mutants. Given the nature of the side chain of this residue 
and the opposite effects of mutations of this locus, it is unlikely that this residue 
interacts directly with 0 proteins. It therefore appears that this locus is important in 
allowing the assumption of a tertiary structure of IL-3 in the active conformation that is 
necessary to bind and/or activate 0 proteins [220,222]. Bulky residues prevent this in 
the mammalian GnRH receptor but favour it in other OPCRs resulting in constitutive 
activity. 
In another study Arora et al identified Leul.SS(S8), Leu2.36(73) at the border of and in IL-l 
as important for coupling to Os and the generation of cAMP. The ability of the mutant 
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receptors to couple to Oqlll, however, was not altered [26]. This study therefore supports 
a number of studies showing that GnRH n=ceptors are also able to couple to the Os 
pathway [221,225-227]. 
Tyr7.53(321) is found in TMD-VII as part of a highly conserved NPX2-3 Y motif in OPCRs. 
Through the interchange of n=sidues 2.50 and 7.49 this motif becomes DPLIY in the 
mammalian OnRH receptors. Although Tyr 7.53(322) Ala mutants wen= better expn=ssed 
with the n=ceptor having normal ligand binding characteristics, this mutation completely 
abolishes 0 protein coupling [168]. Tyr7.53(321)Phe substitutions n=sulted in a receptor 
mutant with low expn=ssion, but it seemed to be supercoupled [168]. These findings 
highlight the importance of this residue in n=ceptor activation. Contrary to findings in 
P2-adrenergic receptor the aromatic nature of this side chain seems sufficient for 
o protein coupling to take place [166]. This might be due to the conserved NPX2-3 Y 
sequence being DPLIY in GnRH receptors but further experiments 8R needed to clarify 
this point further. As for other OPCRs, this microdomain seems to be important in 
CRating a flexible hinge that is involved in allowing the receptor to switch its three-
dimensional arrangement between the inactive and active conformations [32]. 
Coupling and downstream signalling 
OnRH n=ceptors interact with trimeric 0 proteins that target phospholipase C. As this 
process is pertussis toxin insensitive it is assumed that the 0 proteins involved 8R Oq 
and/or 011 [10, 11]. When the receptor is in the active configuration, ODP is displaced 
by OTP. This results in activation of the a-subunit of Oqlll and dissociates from the 
Jiy-subunit. The free a-subunit then activates PLC-P, which in turn cleaves phosphatidyl 
inositol bisphosphate into IP3 and diacyl glycerol. IP3 is a small water-soluble molecule, 
which diffuses from the membrane into the cytosol. Here it binds to IP3 receptors that 
activate Ca2+ channels on the endoplasmatic reticulum [10, 11]. IP3 is then 
dephosphory lated and dissociates from the Rceptors resulting in channel closure. Diacyl 
glycerol, however, n=mains in the plasma membrane where it activates Ca2+ dependent 
PKC. PKC is involved in the phosphorylation of proteins and in increasing the 
transcription of several genes. Measuring the accumulation of IP3 in response to ligands 
in combination with binding studies can therefore be used as a tool in establishing 
agonist or antagonist activity of ligands [10, 11]. Despite not being activated by small 
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G-proteins ARF and RhoA. PLO is activated in gonadotrope cell lines a few minutes 
after PLC activation [228]. PLO in turn is responsible for a late generation of OAG 
which might activate Ca2+ independent PKCs [229]. Under certain circumstances. the 
GnRH receptor is also capable to activate Gs which ultimately leads to the formation of 
cAMP [26. 221]. However, the role of this pathway under normal physiological 
conditions is not well defined. The signalling pathways of the GnRH receptor are very 
complex and not the scope of this thesis. They are however comprehensively covered in 
a review article [229]. 
A number of potential phosphorylation sites are found in the intracellular domains of 
the GnRH receptor. They could be involved in modulating receptor responsiveness. 
intracellular trafficking and desensitisation [1] as well as the activation of MAP kinases 
[63]. It has been noted, however, that desensitisation in mammalian GnRH receptors is 
not rapid but rather slow which is attributed to the absence of the C-terminal tail [230, 
231]. As non-mammalian GnRH receptors contain a C-terminal tail and are desensitised 
rapidly it can be assumed that the mammalian GnRH receptors evolved to be 
desensitised slowly in order to facilitate the prolonged LH surge [173. 230]. 
Phosphorylation, desensitisation and intemalisation are complex mechanisms and 
beyond the scope of this thesis and are therefore only mentioned where necessary. 
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Concluding remarks 
It can be seen that there are similarities in ligand binding and receptor activation 
between all members of the GPCR family. Each receptor, however, deviates somewhat 
from the general mechanisms of GPCR functioning as each receptor evolved to 
accommodate specific requirements. One example is that glycoprotein receptors 
evolved to have long N-terminal regions in order to bind their large ligands. There 
seems to be a relationship between the size of the ligand and the size of the N-terminus 
except for in the family C of GPCRs. Another example might be that mammalian GnRH 
receptors have lost the C-termina1 tail. This happened so that these receptors do not get 
desensitised rapidly. Prolonged exposure to GnRH eventually results in a prolonged LH 
surge, which is necessary for mammalian but not non-mammalian reproduction. Major 
thrusts of future experiments will not only be focused on mechanisms conserved 
amongst all GPCRs but will aim at understanding the special requirements and 
mechanisms needed for the proper functioning of each individual receptor. 
The cloning of a number of mammalian GnRH receptors revealed high homology 
amongst this group of receptors (>85% sequence identity) and very similar ligand 
selectivity and pharmacology [1]. However, the effects of GnRH analogues on hormone 
release from primary cultures of pituitary cells indicated that non-mammalian GnRH 
receptors have distinctively different pharmacologies [2]. Pharmacological studies on 
non-mammalian GnRH receptors recently cloned from catfish [3], goldfish [4, 5], frog 
[6, 7] and chicken [8] confirmed this finding. Notable differences in pharmacology 
between the mammalian and non-mammalian GnRH receptor are that (a) agonists have 
different potencies in the mammalian and non-mammalian receptors, and that (b) 
certain antagonists of the mammalian receptors behaved as partial or full agonists in the 
non-mammalian GnRH receptors such as the X laevis GnRH receptor [2, 8]. GnRH 
binds to the extracellular loops and the superficial regions of the transmembrane 
domains. It was therefore likely that the extracellular loops would play a role in high 
affInity binding of agonists and in conveying agonist and antagonist activity to ligands 
in the different receptors. Extracellular loops of the human GnRH receptor were 
therefore replaced with the equivalent domains of the X laevis GnRH receptor to 
identify which domains are important for these phenomena. 
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This thesis focuses on the differences in pharmacology between mammalian- and 
non-mammalian GnRH receptors and tries to elucidate which regions and residues are 
conveying some of these differences observed. One aspect investigated was to identify 
regions that convey different agonist affInities to the X laevis GnRH receptor compared 
with the human GnRH receptor. The main focus is to try to identify residues that confer 
agonist activity to certain antagonists in the human GnRH receptor. The findings will 
help to acquire more knowledge about the ligand binding pocket and mechanisms 
underlying receptor activation in different subtypes of GnRH receptors. 
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CHAPTER 2: MATERIAL AND METHODS 
This Chapter outlines materials and methodology used in this study. The construction 
and characterisation of a human GnRH receptor containing silent mutations to obtain 
restriction enzyme cutting sites, as well as the iodination of GnRH ligands was deemed 
as basic groundwork which would not merit a separate chapter. Results of these 
experiments are therefore covered in this section. 
GnRH Analogues 
Amino acid residue 
MW 
Peptide 1 1 3 4 S 6 7 8 9 10 
AgoDlsta 
mGnRH pOlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2 1411 
[GIn'lGnRH • • • • • • • Gin • • 1267 
GnRHn • • • • His • Trp Tyr • • 1463 
[D-Trp']GnRH • • • • • D-Trp • • • • 1312 
GnRHA • • • • • D-Ala N-Me-Leu • Pro-NHEt 1294 
ADtagoDlsta 
Ant 135-18 Ac-D-Nal(2) D-4-CI-Phe D-Pal(3) • Ile D-Lys(iPr) • Lys(iPr) • D-Ala-NH2 1311 
Ant 27 Ac-D-Nal(2) D-a-Me-4-Cl·Phe D-Trp • Lys(iPr) D-Tyr • • • D-Ala·NH2 1614 
Table 4: Table of GnRH analogues and their molecular weitghts (MW) used in this study; amino acids in common with mGnRH are indicated by .. • .. ; 
Nal(2): 3-(2-napbtyl)alanine; Pal: 3-(3-pyridyl)alanine; Lys(iPr): N-isopropyl-Iysine; 4-C1-Pbe: 3-(4-cbloropbenyl)alanine; a-Me-4-CI-Pbe: 2-methyl-4-
( cbloropbenyl)alanine 
Peptides in Table 4 were prepared by solid-phase synthesis in our laboratories and purified by C·18 reverse-phase chromatography to more than 
98% purity. 
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Introduction and Effects of Silent Mutations In the 
Human GnRH Receptor: 
To detennine the function of tile extracellular loop domains, the three domains were 
replaced in the hwnan GnRI-[ rt.'(:eplor with Ihe I:quivalent parts of Ihe X laevis OnRH 
receptor. As there was only one naturally occurring unique restriction endonuclease 
cuning site dose 10 the extracellular end of the TMDs (PflMI in TMD-II, Figure 6), it 
was nttes.sasy to introduce suitable cUlling siles in10 tile human GnRH receptor gene to 
allow exchange of extracellular loop domains and 10 introduce poim mullilions in EI.-2. 
Silenl mutations were introduced inlO the human GnRH receptor to obtain unique Seal, 
BsrGl. Stu], Hpal and Snail! sites al the extracellular ends of TMDs Ill-VII (Figure 6) 
using tile Kunkel Method ([2J2J. Figure 21 in Appendix J: for primer sequences see 
Appendix IT). Another two restriction sites were introduced by silent mutations near the 
i lltra~eUlilar end ofTMD-1l (Nrul) and at the intr:lcelhllar elld of TMD-VIl (Vsp!) for 
other projects (for primer sequences set" Appendix II). Mutations were verified by 
manllol sequencing (T7 sequenase kit. Version 2.0. Am~rsham. RSA). The resultant 
receptor showed bindin.: properties and secondary messenger responses identical to 
those of the wild-type human GnRB receplor (Figure 7. Table 5. Figure 8, Table 6). 
Expression of the enginl.'ereO receptor also seems normal as the 1013.1 counlS bound in 
tile absence of cold ligand were equivalent to le'·els measured in the wild type receplor 
(Figure 7) . 
• 1leuro 6, Human GnRH ,eceplOr wilh ~ngin"",ed .esIl iclion endonucte_ cuuini .il •• nc .. I~e 
cxl<aceliula. end cfThlD-1I1 (Scol). TMO·IV (Ru<ll). TMD-V (Slul). TMD-VI(SnaOl) and 
TMD-VII (Hpal). rnMI nn.. the e"lrJiccliular end or HAD-II if a naturally ooc:wrini cunini 
.ite. 
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-9 -8 -7 NSB 
log [cold mGnRH) 
.... t~ .. 7: Bindi,. HAy \0 roIIIpIR .m"~1CS of ,.,('jaMJ . in lht .. ilel-!)'"" INman onRH m!eplOl' and.be 
en,;neerrd human GnRl1 ro«pUH w.h Uno J,lclll mUllunn •. Dua pu..,,,,od are I 
"'IftfOIIl3uve ohl 1_ thr« i..Jepolli,\ml up"" ..... 1l. 
LigaOO IC~ of wild-type (nM) Ie,. of engirw:ered GnRII-R (nM) 
mGnRH ·tlLt 1.2 4.4 '" I.S 
100nllGnRH 174 :to 69 164:1:43 
GnRJ~ II 39* 9 60:*:10 
. 
n .. 5: Compu.",n of Ie ... of vatIQUII hpndJ lOr 1M ... ,Id.,ype """'all Galll i .e«p1or and lb • 
.... infttaI human GnRIl r«eplOr """,linln,l,knl /,u,riaIM .he,," Dill. prtscmcd 'f •• 
....... of II lelIA lIRe indopon6ml uperitncms. 
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·n -10 -9 ., ., 
log [mGnAH] 
~ig .. r. 8, lP .... y I<> com~ .m.aei ... "r mGhR1 1 in (he wild.type hum." G"RI I =<1''''' and the 
<nllin«red human anRH receptor ",i,h .even silent "'"'alioM. Dill. p.«cnl.d arc a 
",prnonutive of III Ita<! rhr ... ind.pond.", expotitnelu1. 
Ligand EC", ofwild-lypc EC~ of engineered GnRH-R 
mGnRH 0.02 ± 0.005 n.06 ± 0.02 
[Gln"JGnRH 0.9 :1: 0.1 0.6 ± 0.2 
GnRil ll 0.5 ± 0.2 1.6 ± 0.3 
Tabl. 6: COIIIpari,,,,, of EC~ of vat"'U' ligand. in the wild-type human GnRH ree.plN and Ihe 
o;nz;i"",,,d hun,"" anRH ",cefUI>( cOll!3ining .ilent restric,,,,,, .1", •. Dall! pr_n~ arc a"""" 
of II ICalollhree indtpmdtm eXp"nmtnlS. 
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Construction of Extracellular Loop Chimeras 
For a now dingram of the cOnstruction of cXlmceliuJar loop chimeras sec Figure 22 in 
Appendix I. Chimeric GnRH rccepwr5 were constructed by excising the extracellular 
loops of the human OnRJ-I receptor and rcplllCing them wilh Iho:;e of the X. lUl"-;s 
GnRH n;:c~ptor using suitable reSlrklion sites. Extmcellulnr loops I. 2 and 3 of the 
X. Juel';s CnRl-] n:ccplor were amplified by I'CR using proof-reading Ikcp-Vcnl DNA 
polymerase (New England Biolabs. RSA) and mutagenic pnmers Onllkcd by the 
IIppropr iate restriction endonuclease CUlling siles (for primer sequences sec 
Appendix 11). The peR products were precipitllted, digested wi lh toc lIpproprimc 
restriction endonuclcascs arK! gcl purified. Extracclltdaf loops L 2 and J of the X. [uevis 
GnRI-! m:cptor were then ligated into the appropriately digesTed human GnRH receptor 
in pBllICscript SK( -) (Stratagene, RSA) to produce chimcric reecptors 1_ 2 and ) (Cli R-
I. CHR-2 and CHR-3. respectively). Recombinant colonies were scl'CCncd for corre<;;tJy 
sized r«eptors by colony PCR SCl'CCning ;!I1d restriction endonudeasc digcstions. 
Positive plasmid~ were used to subclollC the chimeric rtXeptors imo pcDNAl/Amp for 
expreS5ion and characterisation of the receptors in COS-l cells. All sequences were 
confim1ed by manual sequencing. Residues substiTuted can be seen in Figure 9. 
The following chimeras were constructed replacing sub regions of EL-2: (a ) residucs 
IIC IiI to &r111 in the human GnRI-1 receptor ..... cre replaced by Arg' U to Asnl..:t of tnc 
x: laev;s GnR!! receptor (CHR-4, Figure 10). (b) residues Ile lli to Val 191 of the human 
GnRH recepTor were replaced by Argl1< 10 Asn lJo of the X. laevis GnRH receptor 
(CHR-5. Figure 10) (EL-2 in thi s cons1ruet has the same length as EL-2 in the X. loevl1 
GnRlI receptor). (e) residucs ]>hel~J 10 Glnl", in the human GnRII recepTor were 
replaced by phcll l TO Gh, I'<II of the X. laevis GnRH l'IXepTor (CIIR-7. Figure 10). and (d) 
residues GI)'I" TO Glnlal in the human GnRH receptor were I'\!plaeed by PheUi to Glu l'l6 
oflhe X. lae"is GnRH receptor (CHR-6. Figure 10) (EL-2 in this construct has the same 
length as EL-2 in The X laevi! GnRl1 receptor). 
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flRUff" It"","" C,nRU _"plot ... ,,10 .ikn, mul.""n. to .11_ (or chim ... ic u.da .... " of do" 
exu.ccllull, bopL Red raidua indic-*c X 1 ..... 10 Gnkll ""'CPO< mOd"", in El_1 ,,11;'1\ 
an: d'O"tl"lII .:ompar." .. j,h ,he h ...... !oC<I""""'. 101"" ..... ~ indicau X. liM ... GrlRH 
r«cpOf tal"".., .n the N-tct"" ... 1 ~ .. r El-2 .. hoct. .c dlrr=- COSIIparN wilh ,"" 
!\um., soqllC!l<;t. .'WI ,"id~ .... mod,," IlOl jlfosm\ ill ,,'" X I",yu GnRH '=p1or. 
blad; rnid_ an: X IQrTU GnRII tll«f*lr m.dun ",tho C-_, .... R<:lion o(El.-2 wtoid! 
..., ddf ... tfII CORII*od " -,,II 1M II ........ ...,..""'e. IIId yellow mid,," Indi<OIc X. /on'a 
OnRI! ICCqlIOr mKl...., ill EL-l "lIldo." dirk"'" '*"I*N ... ldI' .... IounI ... scquetIn'. In 
CltJl..2 blue IIId blll<~ tn~ ""c ....... ~uIed .. hik IIw ~ raidllel "efC dolo'lOd. In 
CHR-4 """ ., 101 .... rnHl_ Wet" ... boIillfICd Add~"",.Jly ItCUI rc:sidun .. ....., dolcled in 
CUR-'. In CIIR-6 .. . 7 bla",~ ..... " wb>t'Wled . .... dd"ion.U)' "=' rn.w... ....... 
lkid<d in CIIII.-6 
FOI emU 4-7 chimerIC anliscMC primers "ere dt'5ignoo for bOlh the human lind 
X. lut,.fs GnRH rc(:cplor containing 18 bases of the other receptor at their Y end !O 
produce the COn5lrucl5 sho .... " in FiGure 10 (ror primer sequeflCltS $e,' Appcndill II), 
These primers wen: used In eombmation wnh a sense primer, "hich llIi!;llcd to !he 
N-Iennin.al pottiOfl of £1..·2 eOlluailllllg the OsrGl recognitIOn wquence at Its 5' end, A! 
Ihe same time the C'lennmal !leClion of EI.·2 of the Olher !'eCltplOr WIl5 amplified using 
a sense prim",r camplmumtar)' 10 the 18 bases on the chimeric primer and an Wltisensc 
pnml.'r which aligned 10 the C·termlnal seclion of £L·2 eontaining the Slut rl.'Cognilion 
!ieljueocc 5'. In II second round or f'CR lilt: tWO productS oflhe firsl round of I'CR Were 
used in combination wilh primers containing the OsrGl and Stut recognition sequcnc",s 
(from earlier mutagenesis eKpo:rlments) 10 IImplil}' the fulllltngih chllneric EI.·2. Since 
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these chimeric /\,'CeplOrs "'ere flanked by BsrGJ and Stu] si tes Ihe resultant chimeric 
fragments were cloned into the human GnRH receptor identical to Ihe way CIIR-2 was 
cloned. A now diagram of Ihe construct ion of these chimeras is sho .... 'll in FigUTC 2J in 
Appendix L 
17' 180 lSI 184 t9J 1% 
~ ~ ~ ~ ~ ~ 





CHR7: " __ un 
human GnRH-R: IHLAD5SGOTKVFS QCVTHCSFSQh~rlQ 
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181 181 193 197 205 208 
nKUr. 10: ComparilOfl Qr tho x. '''''''IS (lOp) on! human (bonom) EI.·2. 80kIleners indicMt constrWd 
relid ...... To show tho a>nslnll:tion of CIIR·2 ..... "·7. solid box ... indio_ X. hx~is GnRIl 
"",cpt"" <Hi ....... "'h;~ opm box .. represent lilt".,...., GnRH reuptar rtsi<koes. 1M dashed 
\ ..... tCpr .. efIU I '"1' or 5 Im;1IO .,ids in 1M X fDnis GnRlI ncepIOr _ ...... It.! 1M 
X iani. EI..2 .... El·2 of CHII..2. CItlt.S ond CI IR·1 '" 5 _ino Kids shoner man !he 
"""'-' GOIRII receptor EL·l. 
Point Mutations in the Human GnRH Receptor 
Point mutations wcn: inlroducc-d into tile hum1lll GnRH receptor using II PCR based 
method similar to the one used to c reale chimeric m:eptoIll4-7 (Figure 2]). Antisense 
pnmtTS .... eM constructed containing the wanted mutations nanktd by at least 12 bases 
of the wild·typt sequence on either side. Sense primelll ..... ert: constructed to align ..... ith 
the 12 bases s· or the mutalions o n the antisense primeB (for primer seqllllnce5 see 
Appendi/( II). Anti~1\SC prinM:rJ ..... e,.., used together with S P6 lind ,e~ prime..., 
lOilether with T7 10 obtain t ..... o PCR products. These products were ~d together as a 
template in a st'Cond round of PCR in .... ,hich T 7 and SP6 ..... ere used to obtain the full 
length mutant GnRH receptor. All pe R react ions ..... ert: performed using Deep-Vent 
DNA polymerase (Ne ..... England Biolabs. I lot fordshire. UK). Tht resultant mutant rcR 
products Wtrt: pre<:ipitattd. dilleSled .... ilh the appropriate restriction endonucleases and 
gel purified. Tht mutant m:cptOrl ""e,.., then cloned into pcDNAIIAmp and sequences 
were confirmed by autom:\led sequencing (ABI Prism. I1igDyeT" Terminator Cycle 
Sequencing. Perkin-Elm ... r Applied BioS) Stcm$. WarringlOn. UK). 
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Transfection 
DNA for Inmsfection was prepartd usinG Qial>tn (We$l Sussex, UK) Ma..'l:ipreps. COS·1 
ce lls "'"ere maintained in Dulbecco' s modified Eaglc ' s medium (DMEM) cootaining 
10% foetal calf serum. The cells ... ere lransfecled as previously described Ill3]. Cells 
w~rc seeded al a density of200 000 to 300 000 ce lls per well in DMEM containing 10% 
foetal calf serum. penicillin (0.2 Ulml) and stI"CptOOlycin sulphat!: (IOOIlg/ml) into 12 
well plales (Coming, Bocks. UK) cooled , ... ith poly. i). Lysine, DNA was tra/lsfc:ctc:d 
using an llllaptcd DEAE·Dexlrilll ml'thod (2331. COS-I cells W~ incubaled for 4h in 
serum free DMEM cOlitaining DEAE· DexIr1lfl and 2118 of DNA. This WIL5 followed by a 
60 min incubation in DMEM containing 2% foetal calf serum and chloroquine 
(200 JIM) and by a 2 minute dimethylsulfoxide shock. Transfccted eo: lIs were grown for 
48h in DMEM containing 10-,4 foetal calf serum IlIld IlIllibiolics prior 10 IP and binding 
c:xperiments. 
Inositol Phosphate Assay 
lP assay! were carried out as previously described [233[. Briefly. Iransfected COS-I 
cells ""Cre labelled for 16-ISh in O.Sml Special DMEM wiihout inositol (Gibro BRL 
RSA IlIld I'ais ley. UK). contDJrung.l% foe\.D1 tal f serum and 21lCllmi myo(2.' HJinosilOl 
(Amcrsh:lm. RSA and Buckinghamshire. UK). Cells were stimulated in ihe pn:sence 
andfor absence of ~onists and antagonists in Buffer I (140mM NoCV4mM KCI!2OmM 
Hepesl8mM glucoselO. J% fauy-acid-free USA/lmM CaChi l mM MgCIz. pH 7.4) [233] 
containing JOmM LiCI for 60 minutes. InosilOl phosphates " 'cre extr1lcted at 4°C "'ilh 
IOmM formic acid for a minimum of30 minutes [234J and sepDr1lted using a Dowex ion 
exchange resin as pn:viousty described [233J. Total inositol phosphates were eluted and 
radioactivity was measured using a scintillation counter. Basul IP production was 
measured in tiM: absence of ligand. There was no significant difference between basallP 
and mocl.:-lransfeckd cells stimulated wilh 111M mGnRH. 
Receptor Binding Studies 
IlJ I_GnRtl A used for radioligurnl assay~ fur PgoniSIS was radio-iodinated as previously 
described [233J using chloramine T. Uricfly. SilK of peptide was labelled in a O-SM 
phosphate buffer in the presence of I .OrnCi Illr . The reaclion .... 'lIS staned by adding 
chloramine T 31 a final concemmlion of 2.SmM. After 10 seconds Ihe reaction was 
slopped by adding sodium-me/(J·bisulfile 31 a final concenlrat ion of 3mM, The 
radioligand ""as purified on a CI8 HPJ.C column using an acctonitrile gradient. A 
Iypical elution profile is sho ..... n in Figure I I. The assay was caTTied out as pre",iously 
described [220[. TransfeCled cells ..... ere incubated ..... ith 100000 cpm tlJI_labeJled 
GnRH A in 5001-11 Buffer! in the p~senceJabsence of cold ligand for 2 hours. Cells 
were ..... ashed 2)( with icc·cold Buffer I containing 0.50/. BSA before being lifted with 
1.0ml O.IM NaOH lind radioactivity was determined. Non·specific binding was 








o,~~--~------~~~~~----~-o 10 Wl4 
fr~ etion (1.5 ml ) 
fi, .... I I: Rep' .. ..,l/IIin ~I,,,ion profitt .11 .. iodl"",ion ofGnlnl A on I CI8 IIPLC column ... iftl an 
acttonitri l. gradi ent for elulion: in this iodi,u"ion samples fractions 23 10 2S ... r. 
individually t.sted before u,. in re<:eplor binding ... say .. 
t.!!lI-[O:rrp"]GnRI-I used for radioligand assays for Atllagonist 135·18 was radio· 
iodinated using the ladagen (Pierce and Warriner, Chester, UK) method. Briefly, 5f11 of 
ImM (1).TrpO[GnRH was iodinated in phosphate buffered saline in the presence of 
40!lg lodogen lind I.OrnCi WI'. The reaction was stopped after 90 seconds by adding 
5001-11 elution buffer (O.OI M acetic ocidlO. I%BSA). The radioligand was purified using 
a Sephadex 025 colunID using the elution buffer. A typical elution profile is shown in 
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Figure 12. Transfecled cells were incubated with 200000 cpm IUI·labelled 
ID.Trp61GnRJ-I in 500111 liEPESlDMEM + 0.1% BSA in the presenceJabsence of cold 
liwmd for 2 hours. Cells were \~iashoo 2); with ice-cold phosphate buffen:d sa/ine before 
being lifted with l.Oml O.IM NaOH and radioactivity was dete rmined. Non-specific 
binding was det~rrnined in the presence of I IlM unlabelled Antagonist 26. 
, 
• 
fl1l~tlon (5 mil 
filtDr~ 12: R~ntalive clotioo protile .n., iodinalion of ID-T'P· )(JnRH On' Scpha<k~ 02~ o;olumn 
.. inll a.alM ""<'lie: acldlO, I%1ISA fOf .lulloo; in ,hi, iodin'llon oampla between ftK'lioaJ 
17 and 23 ",ere pooled. alliqooled and 10Sied befOre .... in reccpror bindin8 1IS$I)'5. 
" 
Data Analysis 
Experiments were carried OUI in dupIiCllt('. Graphs sboV.ll art 11 representath'c of at least 
) independent uperiments or the nw:1IIl of at least} independent c:rtpcrimcnts. The 
graphs were ploned and IC,o and EC"" values were obtained using the -One site 
rompetilion~ formula of Prism* Version 2.0 (GraphPad. San Diego. USA) for the lClQ 
values and MSigmoidal dose n:sponse~ formula of Prism* Vtrsion 2.0 (Gl'llphPad. San 
Diego, USA) (Of the EC,. values. 
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CHAPTER 3: AGONIST ACTIVITY OF ANTAGONISTS 
IN CHIMERIC AND MUTANT GNRH RECEPTORS 
Introduction 
Oi'eRs are involved in a number of important physiological systems. Since antagonists 
and illverse agonists are able \0 bind 10. but cannot activate GPCRs. receptor activation 
plays a crudal part in re layillg a signal into the cdJ. The identification of dClcnninams 
orche rct:cplor and ligand which can ~1ab jli sc the receptor in an active or inactive stale 
would be fundamclltal for uooerslanding molecular mechanisms of rct:eptor activation 
and therefore be crucial deumninants in developing novel drugs for the treatment of a 
number of diseases. 
As discussed in the introduct ion. the d~lcrmjnalion of the precise molecular 
mechanisms underlying rcecplOr activation is a major challenge in understanding the 
functioning of GPCRs. Gi ven that ligands can vary considerably in size and struetlUC 
even for the same target rceeptor [15]. it is difficult to d issect ,",'hich residues and 
domaiM are involved in activlIling the receptor by stabilising the receptor in the active 
state. [n the extended ternary compJe~ model it .... 'as proposed that GPCRs can exist in 
two conformations. lhe iMctive or R state and \hc active or R· state I[ 16-1 [8]. As in 
the abscllCc of ligands GPCRs an:: predominantly in the R statc. tocy arc be lieved to be 
constrained in this eonfonnation. The cnergy barrier betwccn Rand R· . ho ..... ever. is low 
cllOugh for some receptor.; to spontaneously switch to the active conformation. In the 
absence of ligands. the equi librium is generally very much in favour of the iMet;v(' 
conformat ion. al though some receptors an: active at any given point [[ [8). The present 
IlOtion is thaI a ligand has high affinity for a defillCd conformation of the receptor [117. 
118]. Upon binding to the receptor the ligand Slabilises Ihe receptor in thi s particular 
conformation. thus removing it from the equilibrium between unl iganded R and R· . 
Antagonists are thoughl to bind equally well 10 the active and inactive states orlne 
receptor and therefore preserve the equilibrium. lnvcrse agonists arc be licved to bind 
predominantly to Inc inactive state [117]. In the wild-type GI'CR. both antagonists and 
inver"", "soni .u; therefore do nol chanse or even lower b3$ll1 secondary mc."",nscr 
production. Agonists. however. preferentially bind to activated receptors. As a 
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consequence the equi librium shifts towards the Il(:live conformation. Agonisls arc 
lherefore able to produce an elevated secondary messenger response on the basis of 
l:onfotmDliol1al selectivity (IS] . This theol)'. however. is dispul~>d by NOOa eL al [106] 
who argue that the agonist plays an active role in inducing the active conformation, In 
their poper !he authors argue thal an illlernclion between Tyr' of angiotensin II and 
Asnl.J~ III ) on the ATI-angiotensin II receptor is needed \0 release Asn1l.l(lIl ) from a 
conslruinllMI sUibilises the receptor in the inactive confotmDlion. When this cOllslrainl 
is released, either by agonist binding or by mutating Asn l-1Sl.IIIl, the receptor assumes an 
intermediate R' conformation before i1 becomes fully activated by olher interac tions 
between the agonist and the receptor. Another group identified the possibility of Wl 
interaction between Tyr7.Jjml and AsnlJ ,,111 1 / I 07] . This hydrogen bond might account 
for tnc constraint of the ret;eptor in the inactive state. Upon agonist binding. Tyr4 of 
angiotensin II replaces Tyr7HU9l). which is released [0 bind [0 ASpl.J(l(14) /122]. This 
process represents the first step in a chain of events ultimately leading to full receptor 
activation. This model therefore proposes an induced activation rother than a 
confomlolltiolUll selection of the active state by agonists. Furthermore. this work presents 
some of the first experimental data indicating thaI GPCRs can exist in more than just the 
inactive R and active RO conformations as removal of the constraint on ASIll.l3( III ) does 
IIOt activate the m:eptor fully /106]. The possibility of GPCRs existing in more than 
two states was initially proposed by &:hwanz et al 1235]. h has since been documem~ 
by other groups [15. 124-128]. Whether this mechanism is unique to eenain receptors, 
or whether Ihis is a general mechanism followed by olher GPCRs has yel to be 
demonstmted. 
AnUigunists Wld agonists are ollen stroelumlly similar in nature. II is asswned lhat in 
this scenario they share a similar binding pocket. Wllether a ligand is IlIl agonist or IUl 
antagonist is therefore determined by whether the ligand can or cannot make crucial 
con1.al;1 wilh a specific receptor residue. Ii is possible that residues intemcling with oon-
peptide and small peptide ligands are dim:tly involved in receptor activation or al least 
in veT)" close proximity 10 residues that constitute the receptor activation machinery. 
Residues in\'olved in receptor activation are generally found decp within the TMDs 
[ 15]. l.a rger peptide ligands and glycoproteins ore understood to bind to more 
superficial residues. As discussed ea rlier. mechanisms linking ligand binding and 
reo::eptor 3Cliv31ion for Ihese receplors are therefore more complex. Non-peptide and 
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peptide: agonis1s for the: same: ra:c:plOr (e. g. in the somatostatin recepton (236J) are 
another example indicalill(! that GPCRs CWI ~ ac\ivated b)' dirrerent mechanisms. This 
further complicates proposing a common mechanism of rtCeplor activation for aU 
GPCRs. 
In GnRH rc:ccptol'll non-peptide BIlIOllonists have only been di:Kovcrt:d recently [209· 
2 11 J. To dale:, not much i$ kllo",n aboullhei r method of action and thciT billdinll pockel, 
[n order to explain the mechanisms unde rl yillil activation of GoRH receptors bener. it 
would b~ helpful to delenninc which n:sidues and intcractions of GnRB are needed for 
agonist aeliyi l), . So far the N-tenninal region of GnRH has been idc:n tified 10 be 
involved in conferring agonist aclivi l)' 10 GnRH (Ill> discw>sed earlier. [I]). AI prescnt 
only LYSJJl:( llI) has ~cn implicllled 10 illnuence agonisl bUI nOI anlllgonist binding 1881. 
More infomtatioll about rO:CC'ptor residues imponant in binding li&ands and reeoanisillj 
them as agonisls or antagonists is needed for a funher refinemenl of Ihe reeeplor 
aC lll111lion model as proposed by l1alicsteros e\ al (discussed previously.1l4j). 
On.: of the mos l striking pharmaeolOllical dilTerellCCS of mammalian· and non· 
mammalian GnRH rcceplOl1i is lhal some of the anlllgollists of the mammalian GnRIl 
receptors. such as Antagonist 1)5· 18. aetllS panial or complele allonists illihe non-
mammalian GnRH reeeplors !2, 8). Siudies indicated the necessity of a D·Lys or a 
D·Lys{iPr) in posi lion 6 of lhe HgaJld as crucial for agonisllICl ivity of those: li&ands in 
lhe non· mammalian GnRlI reeeplon; (S] . This chapter anempcs 10 identify domains and 
specific residues thai are needed 10 rewgnise lhese ligands IS agonists. As !he ligands 
are believed 10 mainly billd 10 Ihe extracellular domains of the GnRH rccl:ptor (II . 
EL·I. EL-2 and EL·) of Ihe human GnR~1 ~CplOr were exchanged individually v.i ih 
tbe equivalent regions of Ihe X. fael';J GnRH receplor in which Antagonist 135·18 has 
agonistic properties. After identifying EL·2 as Ihl: major determinanl for conferring 
agonist activi ty to Anlagonisll3S· IB point mU\.IItions v.o:t'C made in Ihe C·terminal 
region of EL--2 to determine the individual amino acids responsible. 
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Results 
Agonis tic/Antagonistic actfvltles of Antagonist 135-18 in 
chimeric receptors 
Extracellular loops of the hum:m GnRH receptor werc individually replaced ,,-im 
equivlllcnl domains of the X. Ille~is GnRH receptor lind tested for their ability 10 
produce inositol phosphates in response 10 Antagonist 135-18. When El..-I (CIIR-I) and 
EL·) (CIIR·3) of the humun GnRII r«cptor were replaced wilh X. fuel'is receptor 
domains. !\nlagoniSI 135-18 was slill unable 10 produce a sc<:ondary messenger 
response (Figure 13). When F.L-2 was replaced (CHR-2). howe\cr. Antagonist 135-18 
was Convened from an antagonist 10 an agonist as the ligand did not inhibit II> 
production in the presence of mGnlUl and alone stimulated the production of IPs 10 
it_cis similar 10 maximal Incls generated by JaIllr81ing conccntnlll ions of mGnRH 
(Figure 13. Figure 14). To delermine ... telher Ihe exchange o f I:.L·2 had an effect on 
other amagonisl$. I\nUlgonisl 27 .... as les!(~d and found to slill heha\C as an anlllgonist in 
inhibiling Ihe II' response to mGnR11 Wigun.· ] S). This coneilltcs wilh AntaJlOnist 27 
being D fuJI anw.gonisl in the X. 1fM'I'ir GnRI-] I'ttCp!OI" (data nOI shown). 
Fic_ .. IJ: TOtAl II' pr<>du<:aI It) n""""lIular loop th'm ..... ,n ",.ponse 104 M ""'''1100;'' IJ'·II ;n 
""","';-10 ~ IP prod""",d. To establish .. I>"", c.tta<:~IIuI ., do"'.;" is (~.poa.ibl~ for 
«Inf"";"" OgOn'St lICI'y'ty '" "",op'''' IH·II COS·I ccll. "'e,e '.lndeClod "ilh 
peON,,""mp ...... lIi ..... "hc humin OnRl1 'oce,"'" 10<1 Ciliu I·J a. dn<:riMd In 
"M ... ial. M<I M","IIoIh~, Fony-ci&hl """rs 01\ .. ""'''focI ion. ceU. "t'. ";mul.u~ wilh 
mGnRH (~.....,) M<I IO~I""",_O)I I J'·I' (""lid b ... j. BosII II' production w" 
mraun><l by ~ ..... riot& ilIc IP p<OIkIa.ion o( IIIbIUnuJ ...... ' ..... (<<,cd c~ lI. (opCn baos), II' 
proWcIioa " .... prflCn,od OS po<C ... IIKC of mbirnal "imul •• lon or !he wild.t)·pc hum.n 
GDRH receptot by mOnRII 0 ... p'"<"t.d or •• tcprc$COIa.l¥c of a, leas, Ib.« 
, ..... pcnJmt UpcI"imcm tarried <lUI in duplk:o", 
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Figy,"" 14: Competition II' ti .. ) (mGnRH vs. "nu.sonis' 1.15-18) and IP respoosc '" All\ai<>nist I J~I 8 
or III<: human OnRIl '''''~pI<>I &00 CIIR·2. To ,how the iII"'goni.ric or ~ni<!ic err"", of 
Anlllg"RlOI I 35.18. COS·, cell' ".'" Ir .... r""'tod .. ,III pcDNAliAmp COlllain in~ .... h ..... an 
wild-lype GnRH ,,,,,.plot (A) ",HI CHR·2 (8 ) .., d • .."i~ in ·'Mat.,.i. 1I ~nd M.'hoos", 
A 
_0 • • • 
i • 1 
" , ~ , 
f<>rTy..,ighi hours .ner .", ... fOClion. cell. "'e", ",imul.,cd wiTh incr.",lng cooccll!ration. of 
AnhlgOni,,135 . 18 in l~ pr ..... nc. (e- IOx higher lhan rhe ED,.., ... ) and absence (_ ) or 
mGnRH. II' production 1' .... m ... ured and "pressed a. a pe,centage of the muimal 
",mulalion of 'he '''''.pl.,.. ,",'im mGnR I!. D.'a p", • .,med .r. a .q,,<scm.,;ve of'" leaS! 
three '!>dependent uperimenlO "" .. ied 001 in duplicole. 
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• _ 0" r • ! " • • • , 
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log(.lnl 27J log[A"'-l71 
f lgu ... IS: Compel";"" 1P assoy (mGnR H \'1. Antagonlll 27) and II' respo~ !O An'.g<>I1iSL 27 of the 
human GnR H ,e""plot ond CHR_2 . To show the &nLP!:onu,ie effect of A nl.OgoniS127 in 
both tbe human Gn RH r~ecPlGr and C HIt_2, COS_I cell. Wer~ ",,",feet.d Wilh 
(>CDNAI/Amp COIllllining the hum.., wild_lype GnRfl r..,.plor iA) and CIIR_2 (9) 11$ 
dc",.ib.,J in " M.'e,ials ..,d M.tltod s~, FOfI~-oll:h' hou .. aflor trOIl.f..,t;"", celli we, • 
• Iimul.,o<! with I",,~"'inl: cOIlccnlrtlliDlls of Ant~""Ut 27 In tho! presence (e- IO~ higher 
'rurn lit. Eo,.) ("-) I<r><l abs"nce (_ ) of mGn RIl , IP prod .... 1ion WIll m .... ured and • • pl"U$fd 
11$ • J>C<OCIlta!>O of the maximal stim"I"""" of ,1M: r«<plOf with mGnRIl . Elata .,...1Cn,e<! 
~. rcpr<:«nlall~ of 0110 .... II" .. ind.pendenl aJ>C,im ... " carri.d OUt In dupl icate. 
EL-2 of the X. Im-,·;s and otrn:r non-mammalian GnRI·1 receptors is 5 amino acids 
shorter than Ihe human GnRH rt.'Ceptor EL-2. According to alignments the equivalent of 
residues 188 to 192 of the human GnRH reeeptor arc missing in the non-mammalian 
GnRl-I reeeptors. To investigate the possible role of this gap and to dctennine whieh 
part of EL·2 confers agonist activity to the antagonist a series of other chimeric 
construc ts were tested (Figure 10). It was found that for all four constructs 
" 
Antagonist J3S- IS was converted 10 a partial agonist (Figure 16). Tile anlal!:onist by 
itself was ubiI' 10 stimulate the receptor but 110\ up 10 the IP .... le vels achieved wi lh 
mGnRH (figure 16), When the percentage activity of Ihe long over the shon COllSlrUC1S 
I>,we calculated (CHR-4fCHR-S and CHR-6/CHR·7. see Figure 10 :md Figure 16) it 
was found Ihal they wen: 107% aoo 75% indicating 1001 the length of tlic loop did nOi 





Fig~~ .6, Total IP produced by ,hott EL.2 "hi nl~r ... (CHRs 4_7) In ""PO"". II, mGnRII , 10· M 
AnI"IIonislI3~-1 8 .n~ basal IP prodll<liQn. To d<1~rmlne which pari of El _2 conferred 
"tI0ni.1 lC1ivilY 10 AnH'goni.! 135-18. COS-I ".11s "'= (n",.feeled with pcDNAJ/A mp 
containing 1"" IuIman wlld-I)I>< rectplOr "nd CUR. 4-7 as dcsc,ibc<l'n " Materials .. d 
Methlhh~. Forty...,iilhr houn .fle. lJ1n>fe<:rioo. ""lis ", ... " 'lim"hued wilh 10" M mGnliH 
(hash.d bon). and 10"/>1 AnlllioniSi 135-I S (50l id bon). Open bar •• ep' ."'"l l>as.al II' 
produclion (measured for mock-l"".f.,Cled cell.). IP producrinn "' ... m.a,ured and 
expreoied .. a percemage of lire maximal Slimulalion of rhe uceplOr by mGnlHI. Dala 
",eKnled ate a repreKnlalive of al lea>1 lh.~ independ"nl experiments calTied oul in 
.... plica1e. Above lire graph the diff.rtnl 1lL-2. of lhe tooslJuclS at. indical.d. BIIC~ boxes 
i.dical" the X loovII E ..... I r",iJlOe$. open bo . .. ace """,.n moOdu ... The x . I""vis GnRH 
re<:epror EL·l il fiy. "",ino acids short", lhan II«: human Gn RH ,"eelllOr EL-2. To 
invesligale lhe cITect oflbe lenglh of EL-2 five "",Ino ..,id. "'''''' delCled in CHR, j or.d 7 
(delelion indic"''''' by lhe dashed Ii ... ). 
Effects of point mutations on the activity of Antagonist 135-18 
As earlier studies identified the necessity of a positively charged residuc in position 6 of 
thc antagonists to be necessary for agonist activity in the chicken GnRH receptor. it was 
possible that then: would be a negatively charged counter ion in EL-2. CompariS()n of 
the sequences in EL-2 revea lcd IMtthcre was a Glu res idue at Ihc end of EL-2 which 
was con!'Crvcd amongSllhe non-mammalian but not mammalian GnRH receptors. As 3 
candidote for a possible interaction ",ilh Ihe amagoniS!. Ihe equivalem residue (Gln2Ol) 
" 
was mutated to Gill. The rcSUltOllt IttCpwr showed no agonist acti vity in response to 
Antagonist 135-18 (Figure 17). As the C· terminal portion or!he x. I~"is EL· 2 has oilly 
seven dilTerences from the human GnRH receptor (Figure 10). these residues were 
in'"estiglltcd to elucidate the ir involvement in conferring agonist aClivity 10 
AmagonislIJS-IS. The seven amino acids were individually mutated in the human 
GnKH rccCpior IlIId tested for their abili!)' to st imulate inositol phosphate production. In 
the Scr!~Thr. VaJ 197AIIl., CyslOOScr, Scr101Thr. TrplO!li is. Ili520JGII'I nnd Gln10'G]u 
mutants Antngonisl 13.5-18 did not stimulate inositol phosphate production signifICanlly 
higher than basal levels (fig~ 17). To invc$tigate the requiremelll$ fo r agonist activl!), 
of Antagonist 135-18 in the C-lcrminaJ section ofEL-2. II series of wmbinatiOIl5 of !he 
mutations were coosuucled. Set l .. , VaJ l~. Se~ and Trp"" were mutlued in the human 
GrlRH rccepror consU'UCtto the residues present in lhe X faev;s receptor (vb'. Tllr, Ala. 
Thr and His res~tivdy). Of al1the possible double amino acid substi tution mutanlS 
only Serl"ThrI1'rp~is displayed pw1iaJ agonistic activit>· (Figure 18). This suggested 
thllt tho:se residucs were importllnt in conferring agonist activity but not su01cicnt alone 
10 confer full agonist activity 10 Antagonist ])5·[8. Triple and quadruple mUlalions 
wcre then studied. Vall91A[aISc~'I11.rfTrp1OJ1tis, SerluThrNal1•1AlalTrp1Oj!-lis 
showed that Anlllgonist 135· [8 was able 10 stimulate IP production 10 about 4O'Y. of the 
maximal stimuhuion [evel. (Figure 19). On the other hand ScfJ~Thrf1'rpa\li s 
and Scrl""ThrNa[ I"7 AlaISc~Th tipple rowants had no agonist activity in response 10 
this ligand ("jgon: 19). This conlirmed the essential requirement of His1lll and A[a l'" for 
conferring .gonist activity 10 Antagonist 135·[ 8. 
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nKur~ 17: TOIaIIP prod~ by point m".fIIS of the h"""", GnRH rKl'ptor in !he C-Iemlh.al section of 
EI.-2 In respolU': 10 IO~1 mGnRH. IO"M IInlAfi:OI\j~ 135-18 ond bNal lP prodllf;\ion. To 
delmn;ne "'~elher ony slnale am;PO odd in lho C-!l:rmIJIII S\!<"I;on ofEI.-2 oflhe hum ... 
Gn RH receptor ~onroned Igon;,,1 aClivity to Anlagon;s. IH-IS, COSO I celli we.e 
•• ansf«led wilh pcDNAJJA,!,p con"';";", !he human "'lld_-_I)"1'<' GnR!! retcplOl' and 
recq>IOfS wilh muwi<ml Ser''''Thr. Var''''AIa. ey.1OOs ... Ser""Th •. T",'tillil• His:o'lGin 
an.! Gln'· 'Glu .. <icK.ibe<l in ~M al •• i.b " nd M.thod .... Fony_eigln hou,l IftC' 
lransf""linn. e<:1I. we", 51 ;m"llled wilh 10""M mGnRH (h."".d ban), and IO"'"M 
Anl3&oniJI 1)5-1S (sol id barf). Open ban rep",,,,,nl basal IP production (measured for 
.... 'timulated traru foo;h,d «oil.). If> production was measlI.ed and .~prnsed .. lporun. 
of Ike rnuimaillimul.I;on of II", wild .. )p" ....,.1'101 by mOnRl1. DiLl prcstnled ...,,, 











FlgUA II: TOOII IP produud by double mUlanI5 of Ihe buman GnRtl ~pI01 in lIIe C-Imninal S«Iion 
of EL-2 in "'SPOOK 10 IO""M mGnRH. IO'"M AIltaiI""'" IJ~II and buIIl tP ",oduclion. To 
deIerm'M wheM I doub," ....... ",n in I"" C'lefmlnal _ lion of EL-2 ofU ... Il uIIIIIQ GnRH 
receplor c""ferred agonist lCIi~'l)' 10 A'""l!""isl 135-11, COS-I cell. we", lran.k<:Ied with 
peONA I/Amp «oma,nlnH I"" human wild-Iypo GnRH roc.peOt and reotplOIS willi mu ... i"", 
indicatc.J below the graphs as de5<:ribcd in ";\uIOril" and Melhods~. fony.., i&hl bours atkr 
If'''Sf<<Iioll, cell. wer. stimulated with IO" M mGnRH (huhed ba .. j, and 1O'"M 
Allaag""iSlI 35_11 (>GIld ban). Open ban "'p",..,nl bual IP produclion (measured fOt 
..... lim .... 1ed tn""fcacd celk). IP "",,;h.eli,,,, ... as ""' ....... d and expressed as. pen:tflaage of 
lb. m&ltimal ' l imulalion of !he wild-type recepto, by mGnRIl. Om pn: •• nled lit 0 

















Flg~~ 19: TOIII IP produced by multiple mUlaOtS of the human GnRlI r<:ceplOr in the C'l<nI1if'llll Kdion 
o f EL-2 in ... pon .. to IO"M mOnRII. 10" ", ArugOllior r 35_1 8 and basal I P production. To 
deferm;"" ",,,,,,he, any multiple muw;an in the C_t ... min.1 .. crion of EL-2 of the human 
emRII '«cptor confornd lion;S! fI<, iv"y t" I\"'lg(>l1;<1 1J~ - 18. COS-I coil, we", ,,,,,,.rocIN 
.... ith pcDNA UAmp tohlain,"s the human wild-type GnRll ",ccP'O< .",* ""'.",oro with 
m"tHI""" indiclled below the P"p,,", as dcscriboed m "M .. er •• I. and MelhodsM • Forty-.~t 
bouts all .. transfccll<>n. cells "'e", .,imulated ",jm 10" '" mGn RII (hashN bars), and 10 1.1 
An",&ooiOl 13S-18 (oolid bilrs). Open bars r~", ... enl b .... 1 IP productlOll (_as".ed rM 
lumlmulalw lran,footed cells). IP prodllClion"as ","""um! ~I>d up'''''''d ... perce'lIq" of 
,h. maximal It;mulldion of the ,,'lId.I)I'" receptor by mGnRH. Data pr.,cnted are a 
,.",.utfltalj.,. of at I."" Ihr.., iOOependcnt eJlpeI';"'etllO ClWficd ()(I t in duplicate. 
Binding of Antagonist 135·18 to chimeric receptors and 
receptor mutants which recognise Antagonist 145·18 as an 
agonist 
To tcst thc possibihty that Antagonist 135·1 8 had gained an cxtra point of contact with 
receptors that recognised Antagonist 135·18 as an agonist. n:ceptor-binding assays wen: 
performed on the human wild type OnRH receptor. and chimeric and mutant human 
GnRH I'Cl:cplors. The leW; of allihese receptors were similar at approximately I x 104M 
(Figure 20. Table 7). The expression levels of all mutant and chimeric GnRH receptors 





10 " • -c , 








>0, b. .. 
" • " -• -c , 
0 
u 50 
~ c , 




~l,u~ U, Compcl~iooo 1H1Od"'s ~'I o{lI. I,,"' ..... GnlUl ~ and dlimrtic: and ......... ~ 
.. -hoch ~n~ ............. is! US-I •• "" "I""Ii' I" dc,,,",,,ne ,he bOwlIn, amnilY (Of 
AIoIallMN US-II. Tn .... .......-.,.. biRdins affilli'Y o f ....... 11"."., IH-li ((II 1hc .. ;ki-'J'P" 
b_ GoIRH"",epWI and tho ~ duo feCUIpI .... lb. I.pnd .. an """,js~ COS- I "",lis 
............. r..,1cd with A: poDNAIiAmp COMIininJ doe human wild-Iype OnRJt I'eCCpIOf IS). 
CHR.2 ( " )' CHR·1 ( AI ) and reaplOI'I .. ill! "'" foH"wi", muwiom: Scr''''Thr. V ...... ALa. 
Scr"'no._ r'1'- Hi. (. ). aood B: 1"'0\,1"1110"", c:onwnin. !he hu ........ Ud-,)P" OnRIl 
~ c-). "ooI ''''AIa, sd"'Tb.. TIp- liis (0). Ser'"'Thr. Val' ..... , T." .... l io ( _) ond 
Vol 'Ala, Trp-ll is (e ) .. d .. cribed in MM..,.W. and M"IK>dI~ fOl1) ..... ;p. hours al'let 
" a ... f«I;OII. «U. "-Ut ;II.ubaied " ilb 200 OOO.pm "'.-[().Trpiollll.l l in lb. 
prcocllCc. ...... """ ofeold "...., ..... , US-II b ~!Iouts. After 2 .. -ul>r ... ilh I'BS ..... II .. 'Of. 
JCllObilioed " ',111 O.IM NtOtl alld IOC&I CQUnU bco.wI ,,'Oft mc .... ed. DaIa )/1<> .... " . .. . ~od.~. "f ..... omaI b"""'''I18o, in .... IIi><cDc< of ",,,,,".11'" US",) .. t.m. 
\be boowd ' .... 1 lias bc<:n __ Ic!d rrom eM COIaI cout\CJ obuoined (y-(eouol counu-b-.l 
__ c.¥(!io-baIII COII<ICS)). 
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Rer~p lo r IC,.{nM) TOla! ~~un:_~l 
bound -;. WI 
wild type: 14:t J lOO-i.2 
CIIR·2 19:t 3 3511 45 
CIIR·7 6.4:t 2.0 12617 
So, Thr. Vol Ala Scr Thr. Trp His mulant 2J:i; 3 120* 4 
V., Ala, Scr Thr. Trp I l i~ mutnnl 16:i:3 156:t 12 
So. Thr, Val Ala. Trp Hi~ mlllDnl 22 ± 4 ]58 ± 9 
Vru Ala, Trp Ilis mU1IlII1 15 ±S 131::>. 8 
Tabl.7: Ie,. of 1."1.110"111 US·'I ond lOla! QlwlIIl bound roo ... ild Iypt and chi",oric aNI mul ..... 
teeqllOI'I .. bidl R>COif\iw At'IIIfOIIiIt IJS-II. an ..... , .. Toul COlI" 'o'aIu .. 1ft I pm:en<ajI~ 
of !he total _I bound ofb ... jld I)pt GnIlH ~ in tho! ",*nce or any cold ~pnd. 
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Discussion 
In recent years a number of studies of GPCRs have demonstrated the conversion of 
antagonists to agonists. Mutations in TMD-III of rhodopsin [237], ~adrenoceptors 
[238], V2-vasopressin receptors [151] and AT lA-angiOtensin II receptors [106, 239], in 
TMD-IV of opioid receptors [240], in TMD-VI of the Dl-dopamine receptor [130], and 
in IL-3 of alA-adrenergic receptors [241] all showed the conversion of antagonists to 
partial or full agonists. 
In a number of studies some of the ligands classified as antagonists had slight agonist 
activities in the wild-type receptors. Mutations often render receptors more permissive 
for activation as the receptors become constitutively active [106, 130, 151,239, 241]. 
Since these receptors seem to be activated more easily, an explanation may be that the 
antagonists had very weak undiscernible agonist activity that is revealed in the 
constitutively active mutants. 
Another explanation how antagonists can be converted to agonists is that they closely 
resemble the structure of agonists but cannot form the crucial interaction with the 
receptor, which is needed to stabilise the receptor in its active conformation. A mutation 
on the receptor could therefore compensate for the shortcoming of the antagonist to 
form this interaction thereby enabling the receptor ligand complex to be formed in the 
active conformation [238]. 
The exchange of EL-2 in the human GnRH receptor by the equivalent domain of the 
X laevis GnRH receptor converted Antagonist 135-18 from an antagonist to a full 
agonist (Figure 13). When only portions ofEL-2 were replaced Antagonist 135-18 was 
converted to a partial agonist, indicating that the entire region is an important 
determinant for conferring agonist activity to Antagonist 135-18 (Figure 16). It appears 
that agonist activity of Antagonist 135-18 is due to a combination of determinants in 
both the N- and C-tenninal portion ofEL-2. This highlights the importance ofEL-2 in 
receptor activation. The length of the EL-2, however, has no influence on whether 
Antagonist 135-18 is recognised as an agonist or an antagonist in the chimeric receptors 
where only small sections ofEL-2 were replaced (Figure 16). 
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It has been reported previously that antibodies raised to EL-2 of the <XI- [242], PI- [243] 
and tn-adrenergic- [244], ATI-angiotensin 11- [245], bradykinin ~- [246], MI- [247] 
and M2-muscarinic-acetylcholine [248] receptor respectively, can activate a secondary 
messenger response presumably by stabilising the receptor in its active conformation. 
This further highlights the importance of this domain in receptor activation. 
When sub-regions of EL-2 were substituted in the human GnRH receptor, only partial 
agonist activity of Antagonist 135-18 was observed while the exchange of the entire 
EL-2 yielded a receptor which conferred full agonist activity to Antagonist 135-18. 
Previous reports from our laboratory demonstrate that D-Lys(iPr) or D-Lys is needed in 
position 6 of antagonists in order for the ligand to act as an agonist for the chicken 
GnRH receptor [8]. If this moiety is also responsible in the X laevis GnRH receptor for 
conferring agonist activity to Antagonist 135-18, a residue conserved between the 
chicken and X laevis GnRH receptor, which is not conserved with the mammalian 
GnRH receptors, would be expected as a possible point of interaction in EL-2. By 
comparing non-mammalian EL-2 sequences a Glu residue was identified at the end of 
the loop which was not conserved in the mammalian GnRH receptors. This residue 
might act as a counter-ion for D-Lys(iPr) in position 6 of Antagonist 135-18. Mutation 
of the equivalent residue in the human GnRH receptor (Gln208) did not result in agonist 
activity in response to Antagonist 135-18. Mutating each of the other non-conserved 
residues in this section ofEL-2 resulted in similar results (Figure 17). 
A number of multiple mutants were made in order to establish the minimaJ requirement 
needed to obtain agonist activity in response to Antagonist 135-18 (Figure 18, 
Figure 19). For Antagonist 135-18 to be recognised as a partial agonist in the human 
GnRH receptor, two mutations (V all 97 Ala, Trp2osHis) are sufficient. A candidate 
interaction is a charge supported hydrogen bond between D-Lys(iPr)6 of 
Antagonist 135-18 and Hi~s stabilising the receptor in the active conformation. For 
agonist activity to be realised, however, a second mutation is needed in position 197 
(Val to Ala). This residue is the equivalent of two turns of an alpha helix away from the 
His. The smaller Ala residue may therefore permit an orientation of the His20S side chain 
to allow the formation of a hydrogen bond with the D-Lys(iPr)6 side chain. An 
alternative possibility is that removing the large side-chain of Val enables the ligand to 
position itself sufficiently close to His20S to fonn the hydrogen bond. 
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Receptor activation is a complex mechanism in which the TMDs appear to play an 
important role. It has been proposed that the rotation of TMDs changes the three 
dimensional arrangement of the intracellular domains which allows interaction with, 
and activation of, 0 proteins [34, 114, 132, 133, 135]. Arg3.50 might playa central role 
in the activation of OPCRs as it is proposed to interact with residues in TMD-I, 
TMO-III and TMO-VII in the active and inactive state [34, 37]. Since antibodies to 
EL-2 can stabilise receptors in the active conformation [242-248], extracellular domains 
might play a crucial role in positioning and stabilising different arrangements of the 
helix bundle. Therefore slight changes in EL-2 have the potential to translate into 
substantial changes in the pharmacology of a receptor by inducing changes in the 
tertiary structure of the helix bundle. 
The binding data revealed that there is no significant change in the affinity for 
Antagonist 135-18 in any of the receptors that recognise this ligand as an agonist 
compared with the affinity of the ligand in the human 0nRH receptor where it is a pure 
antagonist (Figure 20, Table 7). An increase in binding affinity is anticipated if an 
additional contact site is created (i. e. between Hi~05 of the receptor and D-Lys(iPr)6 of 
the antagonist). However most studies reporting mutations which convert antagonists 
into agonists also find no change in binding affinity. Cho et al [130], Claude et al [240] 
and Morin et al [151] all reported similar binding affinities of the antagonist for the 
mutant and wild-type receptors, while Wurch et al [241] reported a small decrease in 
binding affmities (1.8 - 2.9 fold). Strader et al [238] reported a loss of detectable 
binding for the radioligand and were hence unable to make any conclusion about the 
affinity of the antagonist. The only incidence where there was a marked increase in 
binding affinity for the antagonist was reported by Oroblewski et al [239]. However, 
only one non-peptide antagonist was found to have a 29-fold increase in binding affinity 
while all peptide antagonists retained their binding affinities at the mutant receptor. 
Since there is no change in binding affinities of the chimeric and mutant receptors 
which recognise Antagonist 135-18 as an agonist was observed compared with the wild-
type human 0nRH receptor, it is likely that D-Lys(iPr)6 of GnRH forms a charge 
supported hydrogen bond with HiS205 which would only give rise to a 2-3 fold change in 
binding affinity [249]. This may not be easily detectable. Another explanation for the 
failure to detect a difference in binding affinities would be that the Antagonist 135-18 
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forms an alternative bond with the mutant receptor at the expense of another interaction 
which is formed at the wild-type receptor. Instead of binding the receptor in both the 
active and inactive states, the ligand can now stabilise the receptor in its active 
conformation. 
There is an intriguing increase in expression of some of the chimeric and mutant 
receptors, which recognise Antagonist 135-18 as an agonist (Table 7). The observation 
that a deletion of an amino acid in EL·2 leads to an increased expression of the human 
GnRH receptor further shows the importance ofEL-2 in receptor expression [250]. It is 
unknown whether this is due to an extended half-life of the receptor, improved 
trafficking to the cell surface or to an increase in transcription or translation. Further 
experiments are needed to shed light on this. Over·expression of receptors can lead to 
accentuating low intrinsic agonist activity [251-253]. The expression levels of the 
receptors, however, does not appear to be an explanation for agonistic behaviour of 
Antagonist 135-18 as the level of expression is not proportional to the degree of agonist 
activity of Antagonist 135·18 (Table 7). This observation is further supported by a 
mutant CHR-2, which expresses at lower levels than the human wild-type GnRH 
receptor and has the highest agonistic response to for Antagonist 135·18 (data not 
shown). The full agonism observed in the EL·2 chimeric receptor compared with all the 
other chimeric and mutant receptors that recognise Antagonist 135-18 as an agonist 
might be explained by the fact that this receptor seems to be expressed much higher 
than the other receptors (Table 7). As seen in the a2-adrenergic [251], dopamine D4-
[253] and mGlula receptors [252], the potency of partial agonists may increase 
compared with the potency of full agonists as receptor expression increases. This, 
however, might not be the case here, as it is likely that there is a determinant that 
confers agonist activity to Antagonist 135-18 in both the N- and C-terminal domain of 
EL·2 (Figure 16). It is therefore possible that these two effects are additive accounting 
for the full agonism observed in the EL-2 chimera. In future experiments, CHR-4 might 
be combined with the Vall97 Ala, Trp20sHis double mutation to establish whether this is 
true. 
In Summary EL-2 was identified in being an important determinant in conferring 
activity to Antagonist 135-18. The minimal and essential structural determinant in the 
C-terminal domain ofEh2 for conferring agonist activity to Antagonist 135-18 in the 
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human GnRH receptor is a Trp205His mutation combined with a Vall97 Ala substitution. 
However, these mutations are not sufficient to confer full agonistic activity to 
Antagonist 135-18 as seen with the exchange of EL-2 by the equivalent domain of the 
X laevis GnRH receptor. It is likely that full agonist activity can be conferred to 
Antagonist 135-18 when additional mutations are made to the Vall97 Alatrrp20'His 
mutant in the N-tenninal domain of EL-2, as this domain of the X laevis GnRH 
receptor is also able to confer partial agonist activity to this ligand indicating there 
might be another contact point in this region of EL-2. The mechanism invofved in 
conferring activity to Antagonist 135-18 is very specific, however, as Antagonist 27 
retains its antagonist activity at the chimeric receptors. It is therefore proposed that by 
mutating Trp205 to a His, a charge supported hydrogen bond can be formed with 
D-Lys(iPr) in position 6 of GnRH which allows Antagonist 135-18 to stabilise the 
receptor in its active conformation. Experiments are currently carried out where agonist 
activity of Antagonist 135-18 is tested at different pH levels. Protonation of His205 
might impede with the hydrogen bond forming between the protonated His205 and 
D-Lys(iPr) which in tum should abolish agonist activity of Antagonist 135-18 thereby 
strengthening the above proposal. Valin position 197 might be in close proximity of the 
205 locus. A bulky side-chain might therefore interfere sterically, so that the hydrogen 
bond cannot be formed. A small Ala side chain may be necessary in this position to 
overcome this problem. The exact requirement of residue 197 could be further tested by 
substituting this amino acid by residues of different chain lengths (e. g. Gly, which is 
smaller, and Leu of which the side chain is one carbon atom longer). This study 
represents the fust report of mutations in an extracellular domain which confer agonist 
activity to an antagonist. 
85 
CONCLUDING DISCUSSION 
The introduction in Chapter I focused on the molecular functioning of ligand binding 
and receptor activation in the broader context of GPCRs. Current models were 
discussed in the light of experimental data from the literature. The data were taken from 
representatives of a wide variety of rhodopsin-like GPCRs, which constitute the largest 
family of this type of receptor. It was shown that there are similarities in ligand binding 
and the mechanism underlying receptor activation for most of these receptors. 
As opposed to large peptides and glycoproteins, however, small ligands are believed to 
bind entirely within the transmembrane bundle [15, 16, 18]. Potential residues involved 
in interactions with the ligand might therefore also function in receptor activation or be 
at least in close proximity to these residues. As discussed in Chapter 1, peptide 
receptors were shown to involve extracellular domains in ligand binding. Thus the 
binding pocket of these receptors is removed from residues involved in receptor 
activation. Residues involved in linking ligand binding and receptor activation therefore 
may provide a means to fine-tune the efficacy of different ligands. It is possible that 
receptors in which the receptor activation machinery is spatially close to residues 
involved in ligand binding have a highly polarised activity status depending on which 
type of ligand is bound. This scenario would thus minimise the capacity for ligands to 
exhibit partial agonist activity. Knowledge of the configuration of the TMD bundle and 
of mechanisms underlying receptor activation might help designing a small ligand for 
receptors that normally bind larger ligands. This small ligand could therefore activate or 
inactivate the receptor more efficiently than the natural ligands as it binds more closely 
or even directly to the receptor activation machinery. 
An advantage of peptide ligands is the great number of changes that can be made to the 
ligand by substituting a residue. Small biogenic &mines are much more rigid in structure 
and allow very few changes of functional groups. It should therefore be possible to 
analyse the peptide binding pocket in greater detail than the binding pocket of receptors 
that bind small biogenic amines. Small non-peptide analogues, however, are more 
practical for applications as they are easily absorbed through the gut without being 
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broken down. Ultimately advances in the characterisation of ~e binding pocket might 
lead to the design of ligands that can act on a number of different GPCRs. 
It has been shown in the parathyroid hormone (PTH) receptor that the size of the 
peptide ligand may influence which type of G-protein the receptor activates [254, 255]. 
This further highlights the importance of extracellular binding domains in receptor 
activation. It has been proposed that peptide receptors may exist in a number of partially 
activated stages [15]. In view of the findings in the PTH receptors it might therefore be 
possible that different intermediate states couple G-proteins in a different way. 
Depending on the nature of the ligand, a specific configuration of the receptor would be 
stabilised resulting in a specific secondary response for this ligand. This mechanism of 
receptor activation was also proposed for opioid receptors by Selley et al [127]. Further 
elucidation of these problems would improve our understanding of the requirements 
needed to target a certain G protein. 
The second part of the introduction focused on the molecular functioning of the GnRH 
receptor, which was the subject of this study. Although there are a number of 
differences between the GnRH receptor and other members of the rhodopsin-like family 
of GPCRs, mechanisms underlying ligand binding and receptor activation appear to be 
conserved. By working on the GnRH receptors it might therefore be possible to draw 
conclusions for general mechanistics of receptor function for the greater family of 
GPCRs. The work presented here attempted to shed some light on how ligands are 
recognised as agonists or antagonists, the knowledge of which is fundamental to GPCR 
function and could have impact on the design of new pharmaceutical agents. 
Introduction of sUent mutations into the human GnRH receptor 
The first part of the experimental work involved the engineering of the GnRH receptor 
to produce cassettes that would enable the exchange of EL domains. Seven silent 
mutations were incorporated in strategic places into the wild-type human GnRH 
receptor. These silent mutations created new restriction endonuclease cutting sites, 
which are unique for the GnRH receptor. Care was also taken that the restriction sites 
chosen were not abundant in vectors such as pBluescript and peDNA. In fact, most of 
these restriction sites are unique for the GnRH receptor in pBluescript SK( -) and 
peDNAUAmp, which makes these plasmids excellent tools for chimeric exchange 
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experiments. Since the mutations introduced were silent, the primary structure of the 
receptor had not been changed. From IP and binding experiments it became apparent 
that the engineered receptor behaved identically in comparison with the wild-type 
receptor. This new construct was not only used for the work carried out for this thesis 
but also forms an important starting point for a number of other projects pursued in our 
laboratories. One example is a project which attempted to identify the binding domains 
for a non-peptide GnRH antagonist using chimeric receptors between sheep and human, 
where the antagonist binding affinity at the sheep receptor was more than one order of 
magnitude lower than at the human receptor (paper in preparation). 
Characterisation of CRRs 1-3 
The primary structure of all mammalian GnRH receptors cloned to date is highly 
conserved [1]. As expected the pharmacologies of these receptors are almost identical 
[I]. The recent cloning of the first non-mammalian GnRH receptors confirmed the 
hypothesis that these receptors possess completely different pharmacologies [3-8]. 
These non-mammalian receptors are therefore ideally suited to investigate the 
importance of structure-function of certain domains by creating receptor chimeras. 
GnRH is a decapeptide which is thought to bind to the extracellular domains and the 
extracellular surface of the TMDs [I]. EL-I, EL-2 and EL-3 of the human GnRH 
receptor were therefore replaced with the equivalent domains of the X /aevis GnRH 
receptor in the next part of the project to create CHR-l, CHR-2 and CHR-3. Initial 
stages of this work focused on the ability of these chimeric receptors to recognise 
agonists. CHR-l and CHR-3, however, were expressed very poorly and could therefore 
not be used to establish the affinity for agonist ligands. These constructs are currently 
being cloned into an adenovirus vector to increase transfection efficiency in order to 
assess their pharmacology. Employing these chimeras may allow the identification of 
domains that are important for the selectivity of the receptor for certain ligands. These 
experiments could ultimately lead to the identification of further binding sites between 
GnRH ligands and cognate receptors. 
Identification of residues conferring agonist activity to Antagonist 135-18 
As previously mentioned the most intriguing difference in pharmacology between the 
mammalian and non-mammalian GnRH receptors is that the non-mammalian GnRH 
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receptors recognise certain antagonists as partial or full agonists. The third part of the 
project, which is presented in Chapter 3, looked into which domains of the GnRH 
receptor confer agonist activity to these ligands. It was found that the exchange of the 
human EL-2 by the equivalent domain of X laevis, but not the exchange of EL-1 and 
EL-3, conferred agonist activity to one of these ligands: Antagonist 135-18. 
Antibodies raised to EL-2 of a number of receptors were able to produce a secondary 
messenger response [242-248]. EL-2 might be important in receptor activation as it is 
linked to EL-1 by a highly conserved disulphide-bond. Although the extracellular 
domains might not contain much of a secondary structure, this disulphide-bond brings 
some rigidity to the extracellular domains. Furthermore it could act as a hinge 
connecting TMDs II-V which border EL-1 and EL-2. The disulphide bridge might 
therefore be of importance for mediating a co-ordinated rearrangement of all TMDs. As 
antibodies to EL-2 can also activate receptors which bind small non-peptide ligands 
within the transmembrane bundle [242-244,247], it may be possible to activate these 
receptors by ligands that recognise the extracellular domains. Identifying residues that 
are involved in ligand binding and/or receptor activation in the extracellular loop 
domains of peptide receptors may therefore lead to the discovery of universal ligands 
which could be used for a variety of receptors. 
It was previously identified that a D-Lys or D-Lys(iPr) in position 6 of the antagonist is 
needed for it to be recognised as an agonist in a non-mammalian GnRH receptor [8]. 
This suggested that there might be a negatively charged counter-ion in the non-
mammalian GnRH receptors which interacts with this residue stabilising the receptor in 
the active conformation. Indeed there is a conserved negatively charged residue at the 
C-terminal end of EL-2 of the non-mammalian GnRH receptors which is not present in 
the mammalian GnRH receptors. Mutation of the equivalent residue in the human 
GnRH receptor, however, did not confer agonist activity to Antagonist 135-18. Further 
point mutations in the C-terminal section of the human GnRH receptor EL-2 
demonstrated that no single residue confers agonist activity to Antagonist 135-18. A 
series of multiple mutations in the C-terminal section of EL-2 identified that agonist 
activity can be conferred to Antagonist 135-18 by mutating Trp2~ and Vall97 to His and 
Ala respectively. It is possible that a charge strengthened hydrogen bond between HiS205 
and D-Lys(iPr)6 of the ligand can stabilise the receptor in the active conformation. The 
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small Ala side chain might be needed in position 197 to overcome sterle problems 
compromising the interaction when a larger side chain is present. 
The scope of future experiments is to identify further points of interaction between 
Antagonist 135-18 and the N-terminal region ofEL-2, as welI as by expressing CHR-l 
and CHR-3 by means of the adenovirus expression system. These data, together with 
the aid of computer modelling might then be used to refine the model of the ligand 
binding site of GnRH receptors. The model of receptor activation proposed for the 
GnRH receptors might also be improved, which may lead to the design of novel non-
peptide contraceptives or drugs which could ultimately be used in the treatment of a 
number of hormone-dependent diseases. 
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ApPENDIX II: PRIMER SEQUENCES 
Primers used for the introduction of silent restriction 
sites into the human GnRH receptor 
'" 
Bold letter indicate reslri",ion endonuclcll5e CUlling siles. smullle1ler1 indicate changes 
of the wild· type sequence. 
There is II namrally occurring Tthl11 1 (OACNJ.NNGTC) si le III the eXll'lICeliular end of 
TMD-I: 
117 GACC~TTGTC 125 
TMP-lI: 
There is II naturally occurri ng j'flMI site (CCANNNN!NTG) IIl lhe ex tracellular end of 
TM[) .. II: 
310 CCACTOOJ.ATG 319 
A NruJ site (TCJ.OCGA) " 'as introduced near the intracellular end arTMO·II: 
235 AAAAAGCTCTCU GAATGAAGCTG 258 
AAAGCTCTCqeGAATGAAGC 




A Sea.! sile (AGT .LAcn was introduced al the utmccllular end ofTMD-III: 
361 CTCTGCAAAGTTCTCAGTTATCTA 384 
TCTGCAAAGTaCTCAGTTATC 





A BsrGl sile rr tOT ACA) was inlrodoced III the extracellular coo o fTMD·1V : 
538 GGACCACAGTTATACATCTTCAGG 561 
GACCACAGTTgTACATCTTCA 
GPO L YIP R 
t 
llsi llg primer 
TAW-V: 
A Stu! si te (AGG.!.CCI) was introduced ~ar the extracellular end ofTMD-V: 
637 TGG'I'GGCA1'CAAGCATTTT .... TAACT'M' 65] 
GGTGGCATCAgGCcT'I"M'ATAACT 




A SnaB! site ( rACJ.GTA) was introduced L1t chc CKlrocciJ ular end of TMO-Vl 
865 ACTCCCTACTATGTCCTAGGAATTTGGTAT 89~ 
CTCCCTACTAcGTaCTAGGCATTTGG 




A Hpal site (G'nJ.AAC) WIl.'i introduced on extracellular coo of TMD-VII 
922 TTGTCAGACCCAGTAAATCACTTCTTCTTT 951 
GTCAGACCCAGTtAAcCACTTCTTCTT 
LSD P V N H F F F 
T 
using prinll'T: 
A Vspl site (AT l T AA 1) was introduced Ul lhc inll1lccllular end of TMD-VI I using 
primer 10665: 
913 TGCTTTGATCCACTTATCTATGGATATTTT 1002 
GCTTTGATCCAtTAATCTATGGATATT 
C FOP L J Y G Y r 
T 
116 
All the above rcstrictio/l sites an: Llniquc fOf pBlucscripl SK(-) conlaining the human 
GnRII ~ccplOf. VspJ is unlqllC for the re«ptor but then: an: J other VspJ culling sites 
in pSK Blucscripc: 924, 98) + 2218 (plasmid size: 4.0 kb). MlJtagenesis and chimeric 
exchange was Ibc:n:f~ camed 01.11 in p8Juescripl SK(-). 
"7 
Primers used for the exchange of EL-1, EL-2 and EL-3: 
Bold letter ind icate restriction endonuclease cuning sites. small leiters ind icate changes 
of the wild-type sequence; where possible lhe DNA seqt.lence was kept identicallO tbe 
buman wild-type sequence in the TM D regions. Boxes around amino acids indicate 
TMDs, 
XIPflml,~ (97-492): 
This primer is &:signcd for the extracellular end orTMO·11 of the X {Del'is GnRJI 
recepmr. It is a sens.: primer. 
X. lutI,is .. seq .. c".,., 
X I"",>,/.< seq ... 1\C< 
Prim •• seq ... ".;. 
changed amino add, 
V M P L D A I L W N V M 
5 ' GTGAt GCCTTTGGATGCTTTGTGGAACGTGATG 3 ' 
5 ' GATGCCacTGGATGqqT TGTGGAACGTGAT 3 ' , , 
This primer is designed for the cKtraccllular <,nd ofTMO·11 1 ofloc X fuel'is GnR11 
receptor. It is Wl wniscnsc primer. 
X '''''" .... sequen<. 
X. /oe"is seq"''''''. 
p<;rnct seq"c""e 
11_ DNA seq_or 
chAnged ..... ino ..,i<ls 
XIBuGl.~ (97-494): 
GEL S C IK V L N f 
~ ' GGGGAGC'JCTCCtGTAAGGTCC TCAACTr 3 ' 
3 ' CTc:GAGAGoGACATT tcAt(;AG'f TG 5 ' 
S' GGGGAGCTCTCCtGTAAAGTACtCAACTt 3' 
This primer is designed for the extrace llular eoo ofTM D-I V of the X. /UI.'I'/S GnRlI 
receptor. II is a sense primer. 
X. I"",·" ... ""'l"""'~ 
x. 1"""lS sequence 
Primer ""'I,,"""e 
changt'd a",ino lie"," 
Q 1 fLf R L ] R T A P G 
S' CAGCTATTTCTCTTTOGAT iACGTACTGCTCCTGGA 3' 
5 ' CAGCTqT.caTCTTc.G9~TqCGTACTGCTCCTGG 3 ' , , , 
Primers to construct short £L-2 chimeras (CHRs 4-7) 
2a : ~ ' 
11: ) ' GA TCGTCTCrCGIIG .... 
-f,", J ' It.L2IAB. , 98-614) 
~' (EL2,,,,, , 98-61)) 
2b : 5' 
Ib : ) . crr.rCTCiTfTTCAA 
31: " 4 ft : " C 
, 
Jb: " ~b: " 
J ' !£L.2IIUIII, 98-614) 
5 ' (EL21911 • 98-615) 
GGi>.CAGACAAMGTTTTCTC " (£t.2ItIoS. 98-617) CCTGfCTGTtTT~G S' (WI v..a, 98-6161 
TTCrCTCMn;TGTAACN:lt 3 ' IEL2II!ls, 98 -61 9) 
AAGAUAGTTACllCATTGTGT " (E:!.211 So, 98-618) 
hStu! .. : " v AUCOCC:'fG,\:r J' (U-620) 
"9 
Bl.ao:k indicates humnn GnRII receptor sequeoce while red indicates the X lael'is GnRH 
receptor sequence (as in fig ure 23). Where possible silent mUlalions (smalllencrs) were 
introdoco:d \0 crcale restriction cndolluckase culling sill's \0 simplify screening for 
correc:1 chimeric nxcplOfS. For a now diagram or the construction of [lie shon EI. ·2 
chimeric receptors (CIIRs 4.7) see Figure 23. 
120 
Primers used for mutagenesis in EL·2: 
Bold !cuer indicate restriction endonuclease cUlling sill's. small JcUCT!i indicate changes 
oflhc wild-type sequence. 
S,.,IUTllr: 
o T ~ V F SOC V T H 






o T K V r SOC V T He 5 r 
~. CAGACAM.AGTTT'l'CTCTCAATGTGt'AACACACTOCAGTTTT 3' ,. 
" 
TCAAMGAGtGTTACACg qTGTG'I'GACCTCAAAA 5 ' 
AGTTTTCTet.CMTGTGCCIICACACTOCAaTT"I'T 3' 
",u n A 
o T K V F S Q C V THe 5 F 
5' CA(iACIoAANl.TTTTCTCTCAATG1'GYAACAC1I.CTOCAGTTTT ). 
3 ' 1'T1'CAAAAGtGt:G'I"lACACqqTGTGTCACaTCVIAA 5' 
5' AAAGTTTTCACAC"I\.TGTOCCACACACTCCAGTTTT 3' 
T ""un A • • u 
THe s r s 0 ~ WHO A r y 
5' N:N;~TTTCACAAl'GGTGGCATCAGGCCTTTTAT )' 
)' CACG'rCMAAtGqGrTACCACCGTAGTtCGaAAAATA 5' 
5' CTaCAG'M'TTaccCMTGGTGGCA'I"CA.1<GCTTJ'TTAT )' 
hU T _u 
H C 5 r SOW W HO A r y 
5' CACTGCIoG'M'TTTCACMt'GGTGGCATCAGGCCTTTTAT 3' 
" " 
AAAAGTGTTqtqACCGTAGTtCGaAAAAT 5' 
TTTTCACAAc.eTGGCATC~TTTTA 3' , !Lindnl 
chantn! .. 
"1C<I~nc~ 
.. , ""'min .Kq. 
,..imer 
u"'_ w. human ""I. 
prj""" 
HCSFSQIiIiHQAFY 
S' CACTGCAGTT'T'T'I'CACMTGGTG<;CATCAGGCCTT'I' TAT 3 ' 
3' GAC~TCAAAAtG9GTT~tqACCGTAGT~C~T S' 




so w Ii II 0 11 r y 
5 ' TCACMTGGTGGCATCAGGCC'M'TIAT 3 ' 
3 ' GT1'ACCACCGTcGTtCG.·.a.~""T s ' 
5 ' TCACAATCCTGGCAc;c.v.GCn"!'Tl"A 3' 
o U,,"UI 
SO WWHOAFY 
5' TCACAATGG'I'GGCATCAGGCCTTTTAT J' 
3 ' Cl"I'N:CACCGTAcTtC(;uAAA:r 5 ' 
.!> ' TCACAATGiTGGC\TGMQCTT'TTTA 3' 
t IUD4lU 
121 
Tho: inlroduction of Dralll and I-lindlll sites ,,'ere made in order 10 simplify seruning 
for mutant receptor.;. Othrr double, triple and quadruple mutaNS wen: consulIckd by 
cuning and ligating the: approprialc: singleldouble mutants together using the Pst l si le. 
The C)1IXIIlscr mu!iulL Wil$. gift from 0... Adam "."'501\. 
Other primers used 
TI: 5' TAATACGACTCACTATAGGG 3' 
SI'6: S' ATITAGGTGACACTATAG 3' 
T): 5" AAITAACCCTCACTAAAGGG r 
